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When different fields of inquiry have been separately cultivated for a while, the 
borderland between them often provides fertile ground for new investigations.  
 - Allyn A. Young, 1924; quoted in (Granados 2003). 
 
 
 
 
As scientists and public health workers most of us suffer from a touch of 
schizophrenia. Though we may rejoice that there are still a few malaria parasites 
available for basic research we must not forget that we are dedicated to the campaign 
against a disease which, until recently, kept half the world in servitude and today still 
divides the rich world from the poor. Malaria eradication in spite of its technical 
setbacks must succeed, and this alone merits all our efforts. 
 - Leonard J. Bruce-Chwatt (Bruce-Chwatt 1965). 
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Summary 
 
 Malaria is a major contributor to morbidity and mortality throughout the regions 
where it is endemic; there are six species that commonly infect humans: Plasmodium 
falciparum, P. vivax, P. ovale (two sympatric species), P. malariae, and P. knowlesi. 
Historically, it was believed that there was limited morbidity and essentially no 
mortality associated with P. vivax, and so this parasite was not a major contributor to 
disease burden on a global scale. This paradigm is being rigorously re-evaluated, and 
evidence from diverse settings now suggests that infections with P. vivax can be both 
severe and fatal.  
 This increasing awareness has highlighted a critical gap: the vast majority of 
research has been directed towards P. falciparum, and so there exists a decades-long 
neglect of epidemiological and clinical studies of P. vivax. As efforts towards global 
malaria elimination have progressed, two facets have become clear: programs directed 
toward decreasing P. falciparum transmission may have very limited impact on P. 
vivax, and the biology of this parasite (especially that of hypnozoites, the dormant 
liver stages) will be a major barrier to elimination. 
 There exists a large body of historical data on human experimental infections with 
P. vivax from two major sources: pre antibiotic-era treatment for neurosyphilis 
(‘malariotherapy’), and antimalarial drug trials in prison volunteers. These studies in 
controlled settings provided a wealth of wide-ranging statements based on expert 
opinion, which form the basis for much of what is currently known about P. vivax.  
In this thesis, portions of this evidence base have been re-examined using modern 
epidemiological analyses with two primary aims: to critically examine this 
 viii 
accumulated knowledge base, and to inform current research agendas towards global 
malaria elimination for all species of Plasmodium.  
 Specifically, Chapter 1 provides an overview of malaria, including the 
parasitology and epidemiology of P. vivax, and discussion about malariotherapy and 
related studies. Chapter 2 examines geographic variation in the epidemiology of P. 
vivax, especially the timing of incubation periods and of relapses, by broad 
geographic regions determined by origin of the parasites. Chapter 3 reassesses the 
impact of sporozoite dosage upon incubation and pre-patent periods (a critical 
consideration in modern vaccine trials); Chapter 4 provides well-defined 
mathematical distributions for incubation and relapses periods in experimental 
infections, and explores the epidemiological impacts of these distributions using 
simple mathematical models of transmission. Chapter 5 examines the epidemiology of 
mixed-strain P. vivax infections and compares these results with studies in diverse 
murine malaria models and general ecological theory; and Chapter 6 clarifies the 
origin of the Madagascar strain of P. vivax, to potentially provide data to explore the 
emerging awareness of P. vivax transmission in sub-Saharan Africa. Finally, Chapter 
7 concludes the thesis with suggestions for future research. 
 ix 
List of Tables 
 
Table 1. Study population, historical P. vivax studies. ................................................ 25 
Table 2. P. vivax strains included in analysis of geographic variation. ....................... 27 
Table 3. Analysis of sporozoite effects in historical human P. vivax malaria challenge 
studies; vector bite-based exposures. ........................................................................... 45 
Table 4. Analysis of sporozoite effects in historical human P. vivax malaria challenge 
studies; strains from the Southern US. ......................................................................... 47 
Table 5. Cox model analysis of sporozoite effects in historical human P. vivax malaria 
challenge studies; quantitative sporozoite dosing. ....................................................... 48 
Table 6. Poisson model analysis of sporozoite effects in historical human P. vivax 
malaria challenge studies, quantitative sporozoite dosing. .......................................... 48 
Table 7. Analysis of sporozoite effects in P. vivax malaria challenge studies in 
splenectomised Saimiri and Aotus non-human primate models. ................................. 51 
Table 8. Summary of evidence for association between sporozoite dose and 
incubation or prepatent period in P. vivax challenge studies. ...................................... 53 
Table 9. Study population for analysis of time-to-event distributions, incubation 
period (experimental studies). ...................................................................................... 60 
Table 10. Study population for analysis of time-to-event distributions, relapse period 
(experimental studies). ................................................................................................. 60 
Table 11. Study population for analysis of time-to-event distributions in P. vivax 
incubation periods (observational studies). .................................................................. 61 
Table 12. Best-fit distributions for experimental incubation times, P. vivax malaria. 66 
Table 13. Fitted distributions for observational incubation time studies, P. vivax 
malaria. ......................................................................................................................... 68 
Table 14. Fitted distributions for experimental relapse times, P. vivax malaria. ......... 70 
Table 15. Total case counts from epidemic simulations, P. vivax malaria. ................. 71 
Table 16. Study population, historical human challenge experiments with P. vivax. . 81 
Table 17. Study population, murine challenge experiments with P. yoelii. ................ 81 
Table 18. Study population, murine challenge experiments with P. chabaudi (set I). 82 
Table 19. Study population, murine challenge experiments with P. chabaudi (set II).
...................................................................................................................................... 83 
 x 
Table 20. Comparison of incubation periods in human challenge experiments with 
mixed-strain infections of P. vivax. ............................................................................. 86 
Table 21. Comparison of time-to-first relapse (from parasite inoculation) in human 
challenge experiments with P. vivax. ........................................................................... 88 
Table 22. Comparison of time-to-mortality in murine challenge experiments with P. 
yoelii. ............................................................................................................................ 90 
Table 23. Log-binomial models for mortality in mixed infections, murine challenge 
experiments (set I) with P. chabaudi. .......................................................................... 91 
Table 24. Comparison of Kaplan-Meier estimator, restricted mean survival times, and 
risk ratios from binomial models for mortality in mixed infection in murine challenge 
experiments (set II) with P. chabaudi. ......................................................................... 93 
Table 25. Comparison of Kaplan-Meier estimator, restricted mean survival times, and 
risk ratios from binomial models for mortality in mixed infection in murine challenge 
experiments (set II) with P. chabaudi (continued). ..................................................... 94 
Table 26. Comparison of risk ratios for mortality by strains in murine challenge 
experiments with P. chabaudi, using robust Poisson regression. ................................ 95 
Table 27. Comparison of risk ratios from binomial models for mortality in mixed 
infection with AS and CB strains in murine challenge experiments (sets I and II) with 
P. chabaudi. ................................................................................................................. 96 
 
 
 
 
 
 
 
 
 
 
 xi 
List of Figures 
 
Figure 1. Modelled geographic range of Plasmodium vivax, 2010. ............................ 14 
Figure 2. Schematic lifecycle of Plasmodium in human and anopheline hosts. .......... 16 
Figure 3. Kaplan-Meier and flexible parametric models, incubation period and time-
to-first relapse, historical P. vivax experimental infections. ........................................ 28 
Figure 4. Median and 95th centile survival times, incubation period in days. ............. 29 
Figure 5. Median and 95th centile survival times, primary attack to first relapse, in 
days. ............................................................................................................................. 31 
Figure 6. Kaplan-Meier plot for the relationship between prepatent period and 
quantitative sporozoite doses in human P. vivax infections. ....................................... 49 
Figure 7. CONSORT diagram, study populations for event time distribution analysis, 
P. vivax malaria. ........................................................................................................... 60 
Figure 8. Comparison of general probability distributions included within time-to-
event analysis. .............................................................................................................. 63 
Figure 9. Comparison of crude (non-data augmented) data and estimated parametric 
models of experimental incubation times, P. vivax malaria. ....................................... 65 
Figure 10. Comparison of crude (non-data augmented) data and estimated parametric 
model of observational incubation times, P. vivax malaria. ........................................ 67 
Figure 11. Comparison of crude (non-data augmented) data and estimated parametric 
model of first relapse times, P. vivax malaria. ............................................................. 69 
Figure 12. Comparison of simulated P. vivax malaria epidemics. ............................... 71 
Figure 13. Kaplan-Meier curves comparing incubation periods in single strain and 
mixed-strain infections in human challenge experiments with P. vivax. ..................... 86 
Figure 14. Comparison of Kaplan-Meier curves, time-to-first relapse, human 
challenge infections with mixed-strain P. vivax. ......................................................... 87 
Figure 15. Kaplan-Meier and flexible-parametric survival model curves comparing 
time-to-mortality in mixed-strain infections in murine challenge experiments with P. 
yoelii. ............................................................................................................................ 89 
Figure 16. Kaplan-Meier curves comparing time-to-mortality in single strain and 
mixed-strain infections in murine challenge experiments with P. chabaudi. .............. 92 
Figure 17. Idealized ecological/demographic survivorship curves. ........................... 101 
 
 xii 
 Abbreviations 
 
ACT: artemisinin-combination therapy. 
EIR: entomological inoculation rate. 
HR: hazard ratio (effect size estimate from survival models). 
IRR: incidence rate ratio (effect size estimate from Poisson models). 
IRS: indoor residual spraying. 
LLITN: long lasting insecticide-treated bed net. 
OR: odds ratio (effect size estimate from logistic models). 
RDT: rapid diagnostic test. 
RMST: restricted mean survival time. 
RR: risk ratio (effect size estimate from binomial generalized linear models). 
SIR: Susceptible-infected-recovered disease model. 
 
 
 13 
Chapter 1: Introduction 
 
1.1 Malaria within a global context 
Despite decades of control measures and intensive interventions, malaria 
continues to cause extensive morbidity and mortality throughout the widespread 
regions where it is endemic. There are six species that commonly cause malaria 
infections in humans: Plasmodium falciparum, P. vivax, P. ovale (two sympatric 
species), P. malariae, and P. knowlesi; and recently P. cynomolgi has been implicated 
as a zoönosis (Ta et al. 2014). The vast majority of research has been directed towards 
P. falciparum, which is the primary contributor to disease burden throughout sub-
Saharan Africa.  
The most recent reporting from the Global Burden of Disease study estimated that 
in 2013 there were ~166 million (95% Bayesian credible interval: 95 to 284 million) 
incident cases, and ~855,000 (95% CI: 703,000 to 1.03 million) deaths globally 
(Murray, C.J.L. and Global Burden of Disease Group 2014). The most recent World 
Malaria report estimated that in 2012 there were 207 million (95% CI: 135 to 287 
million) cases, and 627,000 deaths (95% CI: 473,000 to 789,000) (World Health 
Organization 2013a). The extensive uncertainty in these estimates highlights major 
limitations in data sources in many high burden countries, as well as differing model 
assumptions, especially concerning the use of verbal autopsy methods.  
From 1955-1972, the World Health Organization spearheaded a Global Malaria 
Eradication campaign. These tightly coordinated regional- and national-level 
programs succeeded in greatly reducing the malaria prevalence in many 
epidemiological settings, but numbers quickly rebounded upon tapering of control  
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activities in many areas. Consequently, research into malaria control and elimination 
languished for decades. However, this situation improved in 1999 with the 
establishment of the Roll Back Malaria programme, and then changed again in 2007 
with the dramatic announcement of a renewed push for the goal of malaria 
eradication by the Bill and Melinda Gates Foundation. This clarion call has greatly 
revitalized malaria research; however, large gaps remain in knowledge of malaria 
transmission and epidemiology (Baird 2007, Cotter et al. 2013).  
 
 
Figure 1. Modelled geographic range of Plasmodium vivax, 2010. 
Source: (Gething et al. 2012) (‘CC BY’ license). 
 
 
1.2 Malaria caused by Plasmodium vivax 
Plasmodium vivax is the major parasite outside of Sub-Saharan Africa, with 
extensive burden in South and Southeast Asia, and in the Pacific regions. There is 
very large uncertainty in the global burden of P. vivax due to reporting biases; the 
most recent estimates are 19 million (95% CI: 16 to 22 million) cases per year (World 
Health Organization 2013a). More importantly, this parasite has a much wider 
geographic range than P. falciparum, and it is estimated that a total of 2.85 billion  
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people (40% of the world population) are at risk for infection, the majority being in 
South and Central Asia (Guerra et al. 2010). Detailed models have also been 
produced that predict the geographic range on a global scale (see Figure 1) (Gething 
et al. 2012).  
Historically, it was believed that there was limited morbidity, and essentially no 
mortality associated with P. vivax, and hence it was assumed that this parasite was not 
a major contributor to overall disease burden on a global scale.   However, this 
paradigm of ‘benign tertian’ malaria is now being rigorously re-evaluated, and 
evidence from diverse settings now suggests that infections with P. vivax can be both 
severe and fatal. Moreover, several authors suggest that malariologists in the early 
20th century were in fact well aware of potentially fatal outcomes from P. vivax (Baird 
2013). 
The general clinical course of infections with P. vivax are similar to those from P. 
falciparum- fever, headache, nausea, chills, and rigors (Warrell and Gilles 2002), and 
severe disease (as assessed by WHO standard definitions for severe malaria) has been 
documented in infections with P. vivax in a range of transmission settings. Case series 
in Papua New Guinea, Indonesia, Thailand, and India have found that 20-27% of 
patients with severe malaria had PCR-confirmed P. vivax mono-infection (Price et al. 
2009), and village cohorts in Papua New Guinea found no difference in the odds of 
severe disease amongst patients with P. falciparum and P. vivax mono-infections, 
respectively (OR 0.99; 95% CI: 0.78 to 1.24) (Baird 2013). 
More critically, there are several aspects that differ in important ways from severe 
disease in P. falciparum infections- hyperparasitemia is only very rarely observed in 
P. vivax infections (where it rarely exceeds 5%); and there is no substantial evidence  
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for cyto-adherence or rosetting of red blood cells in P. vivax infections (Anstey et al. 
2012). These findings suggest that the pathogenesis of severe disease may have 
fundamentally different mechanism in the two species. An immune response-
dependant pathway has been suggested, based on the observation that the pyrogenic 
threshold (density of parasites at first sign of fever) may be significantly lower in P. 
vivax than in P. falciparum infection (Anstey et al. 2012).  
 
 
Figure 2. Schematic lifecycle of Plasmodium in human and anopheline hosts. 
Source: (Mueller et al. 2009) (see Appendix for copyright approval). 
 
 
1.3 Challenges towards elimination of P. vivax malaria 
The major knowledge gaps in the biology, clinical presentation, ecology, and 
epidemiology of P. vivax have been highlighted (Galinski and Barnwell 2008, 
Mueller et al. 2009, WHO Malaria Policy Advisory Committee and Secretariat 2013, 
World Health Organization 2013b), and a recent publication outlines some of the  
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main gaps in current control strategies for vivax malaria, but provides limited 
suggestions for further research, especially regarding epidemiological studies (Shanks 
2012).  
Several aspects of the biology and parasitology of P. vivax have major 
implications specifically for malaria control and elimination programs. First and 
foremost, the existence of a dormant liver stage, the hypnozoite (Greek for ‘sleeping 
animal’), is a critical concern for surveillance towards elimination (Markus 2012); see 
Figure 2 for a detailed view of the parasite lifecycle. This quiescent phase can 
reactivate and allow onward transmission to new vectors in the absence of 
importation events (White and Imwong 2012). 
Secondly, and in contrast to P. falciparum, gametocytemia may occur very early 
in the clinical course of infections with P. vivax. These parasite stages are infective to 
mosquitoes, and so early production leads to short serial intervals with consequent 
rapid evolution of epidemics (Sivagnanasundram 1973, Bousema and Drakeley 2011).  
Finally, P. vivax also exhibits long-latency, where the incubation period (time 
from mosquito exposure to first clinical symptoms) may stretch to 6-9 months; 
importantly this phenotype has been recently identified in tropical, as well as 
temperate climates (Warrell and Gilles 2002, Brasil et al. 2011, Kim et al. 2013). This 
facet of parasite epidemiology is likely to have large impacts on the long-term 
feasibility of the intensive surveillance programs required for malaria elimination.  
 
1.4 Current strategies for control of P. vivax 
There are currently no vivax-specific control measures, aside from a single drug 
regimen- primaquine. This 8-aminoquinoline is currently the only approved drug that 
targets hypnozites (another, tafenoquine, is currently enrolling for Phase III trials). 
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While effective, both drugs can cause severe haemolysis in patients who are deficient 
in glucose-6-phosphate dehydrogenase (G6PD); moreover, there are diverse 
polymorphisms with a continuum of enzyme activity throughout P. vivax endemic 
areas (Howes, Dewi, et al. 2013). There are currently also concerns about cytochrome 
P-450 effects in some populations (Marcsisin et al. 2014).  
However, large efforts are underway to field-test and deploy rapid tests for G6PD 
deficiencies in P. vivax endemic areas moving towards elimination. Beyond 
primaquine usage, the general ‘pillars’ of modern malaria control are applicable to P. 
vivax control and elimination. Primarily, this consists of correct and consistent usage 
of insecticide-treated bed nets (LLITNs), prompt parasitological diagnosis using rapid 
diagnostic tests (RDTs), treatment with quality-assured artemisinin combination 
therapy (ACTs), and integrated vector control measures (World Health Organization 
2013a).  
It has only recently become apparent that as countries with co-transmission of 
both major species move towards control and elimination, P. vivax control lags, and 
this parasite generally then predominates (World Health Organization 2013a). Indeed, 
even the historical Malaria Eradication Program had very limited consideration of the 
potential role of P. vivax in continued transmission, with an implicit assumption that 
control would be equally effective for the two species (Nájera 1989, 1999). It has 
been suggested that current interventions will be insufficient to eliminate vivax 
malaria, and that a deeper understanding of both the parasite and the disease, 
combined with P. vivax-specific interventions, will be required (Mueller et al. 2009).  
To address this policy gap, the World Health Organization is currently developing a 
global plan for malaria control and elimination that explicitly considers the unique 
aspects of P. vivax; this plan is expected to be released in 2015 (WHO 2014).  
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1.5 Malariotherapy and related studies 
Much of what is currently known about the epidemiology and detailed clinical 
picture of P. vivax comes from historical human challenge studies conduced from ca. 
1920-1970. The earliest studies focused on patients undergoing treatment using 
malariotherapy: intentional infection with malaria parasites for the treatment of 
terminal neurosyphilis (Chernin 1984). Later studies that were directed towards the 
development of novel antimalarial therapies began during WWII, and utilized prison 
volunteers at several research centres in the USA; the inherent ethical issues of studies 
within these populations have been examined by multiple authors (Weijer 1999, 
Harcourt 2011, Snounou and Pérignon 2013).  
From a study design viewpoint, these experimental studies utilized 
institutionalized patients, with complete observation and follow-up; however, 
standards of data reporting and analysis within the original publications are inherently 
limited by the era in which they were published. The conclusions in studies published 
from ~1930-1950 utilized very rudimentary statistical analyses, or relied on 
qualitative comparisons between groups. 
Beyond the published analyses, these studies do have several important 
limitations. The exclusion/inclusion criteria employed by the original investigators are 
unknown for these studies, and treatments were not randomly allocated. In fact, 
malariotherapy patient selection was based on overall clinical appraisal, and was 
generally contra-indicated for older patients or those with major comorbidities beyond 
syphilis (Winckel 1941, Snounou and Pérignon 2013); the prison volunteers were 
healthy adult males (Coatney et al. 1948). As such, the reported data represent 
generally healthy, non-immune patients, and therefore may not represent clinical 
outcomes in endemic areas or populations. 
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1.6 Specific aims of this thesis 
The central questions to be addressed within this thesis are: can data from 
historical human infections provide evidence to inform research & policy agendas for 
Plasmodium vivax towards global malaria elimination? Moreover, these studies were 
aimed to generate new insights and knowledge about the neglected epidemiology of 
P. vivax. 
This thesis aims to address some of the limitations within original published 
analyses, and to systematically examine the evidence base for multiple aspects of P. 
vivax epidemiology that have been assumed, or that have become accepted as ‘clinical 
wisdom,’ with limited consideration of the underlying data. Specifically, latency and 
relapse are fundamental and neglected aspects of P. vivax transmission, but the 
biological basis and epidemiology of both processes are poorly understood. Decades 
of expert opinion and accumulated clinical knowledge have suggested a wide range of 
potentially important factors including stress, diet, parasite strains, sporozoite dosage, 
seasonality of infection, drug prophylaxis, and host genetics. However, rigorous 
evidence to prioritize any of these within research or control programs is currently 
lacking. 
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Chapter 2: Quantifying effects of geographic location on the 
epidemiology of Plasmodium vivax malaria 
 
This work has been published as: Lover AA, Coker RJ (2013), Quantifying 
effect of geographic location on epidemiology of Plasmodium vivax malaria. 
Emerging Infectious Diseases 19(7), 1058–1065. 
 
2.1  Abstract 
 The recent autochthonous transmission of the malaria parasite Plasmodium vivax 
in previously malaria-free temperate zones, including Greece, Corsica, the Korean 
Peninsula, Central China, and Australia, has catalysed renewed interest in P. vivax 
epidemiology. To inform surveillance and patient follow-up policies requires accurate 
estimates of incubation period and time-to-relapses, but these are currently lacking. 
Utilizing historic data from experimental human infections with diverse strains of 
Plasmodium vivax, survival analysis models have been used to provide the first 
quantitative estimates for the incubation period, and for distribution of time-to-first-
relapse for P. vivax, by broad geographic regions. Quantitative evidence is presented 
that shows clinically significant divergent responses in non-immune patients, by both 
latitude and hemispheres. Specifically, Eurasian temperate strains show longer 
incubation periods, and Eastern hemisphere parasites (both tropical and temperate) 
show significantly longer times-to-relapse relative to Western hemisphere strains. All 
parasite populations show much longer median time-to-relapse than conventional 
wisdom ascribes. Finally, the distribution of the number of relapses is significantly 
different between the parasite populations in the Western and Eastern hemispheres. 
These estimates of key epidemiological parameters for P. vivax strongly suggest that 
the primary evidence basis for surveillance and control of this parasite needs to be 
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 rigorously reassessed. Specifically, active surveillance and patient follow-up need to 
be tailored to local strains to be effective, and that the origin of infection must be 
accurately ascertained for cases of imported P. vivax malaria. These results provide an 
evidence-based framework for effective disease control with inherently limited health 
resources in support of global malaria elimination. These results also provide 
epidemiological evidence to support earlier molecular and entomology-based 
proposals for the designation of two sub-species, P. vivax vivax (found in the Eastern 
hemisphere) and P. vivax collinsi (Western hemisphere).  
 
2.2 Introduction 
 After decades of limited research attention, the malaria parasite Plasmodium vivax 
has moved onto the global health agenda for two primary reasons- it will be more 
difficult to eliminate than P. falciparum due to dormant liver stages and broader 
geographic range, and the parasite has now re-emerged in previously malaria-free 
temperate zones, including Greece, Corsica, the Korean peninsula, central China, and 
Australia (Brachman 1998, Hanna et al. 2004, Armengaud et al. 2006, Danis et al. 
2011, Lu et al. 2011). Moreover, there is increasing evidence that P. vivax infections 
are not benign, but can be both severe and fatal (Price et al. 2007, Mueller et al. 
2009). 
 A large body of epidemiological and clinical data exists to support the existence 
of discrete strains of Plasmodium within each species. Many studies have provided 
descriptive evidence to suggest that latitude of isolation has large impacts on the total 
number and spacing of relapses: tropical strains generally have a larger number of 
closely spaced relapses, while temperate strains generally have evolved to have a long 
incubation period, allowing the survival of the parasite as dormant hypnozoites during 
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colder months (Myatt and Coatney 1954, White 2011). Additionally, malariologists 
have long recognized that that the incubation period also showed variation with strain 
and latitude (Wernsdorfer and Gregor 1988). 
 Modern research of temperate strains from the Republic of Korea supports these 
observations, and also suggests that chemoprophylaxis may contribute to extended 
latency period (Nishiura et al. 2007, Moon et al. 2009). However, these observational 
studies have been unable to estimate the time from infection to relapse or relapse 
periodicities due to uncertain exact infection times, and no direct comparisons have 
been reported with other strains. A second related study examined geographic 
differences in relapse rate during primaquine therapy for three strains utilizing logistic 
regression, but did not examine relapse time explicitly (Goller et al. 2007). 
 Numerous P. vivax classification schemes have been suggested based on observed 
clinical and epidemiological characteristics, including temperate/tropical and 
temperate/sub-tropical/temperate, Northern/Southern/Chesson-type, among others, 
but quantitative data to support these distinctions are sparse (Winckel 1955, World 
Health Organization 1969, Krotoski 1989). Additionally, recent molecular and 
entomological data suggest that P. vivax may consist of two separate subspecies, one 
in the Old World/Eastern hemisphere (P. vivax vivax) and the other in the Americas 
(P. vivax collinsi) (Li et al. 2001); however, research with other isolates has not 
confirmed these results (Prajapati et al. 2011). These two strains/subspecies show 
remarkable differences in their infectivity to different species of Anopheles vectors; 
however, impacts on human epidemiology have not been demonstrated. At least two 
other subspecies have also been reported- P. vivax hiberans and P. vivax 
multinuclatum- both notable for extremely long incubation periods (> 200 days). 
Although not universally accepted, these sub-species may still exist in northern 
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Eurasia, and their clinical behaviour has been reported to be similar to currently 
circulating strains from the Korean peninsula (Shute et al. 1976, Song et al. 2007). 
From these observations, it has been suggested that P. vivax should correctly be 
considered a species complex (Mouchet et al. 2008). 
 A large body of historical data exist from deliberate laboratory infections in two 
populations: institutionalized patients from pre-antibiotic era neurosyphilis 
treatments, and healthy prison volunteers from malaria drug trials. Using these 
experimental infection data in controlled settings, the relationship between parasite 
origin and epidemiological variables for parasites by location of isolation is explored 
in this study.  
 We quantified the impact of geography on P. vivax infections: identifying 
statistically different epidemiological parasite sub-populations, which reinforces the 
hypothesis that distinct subspecies exist. We provide evidence that parasite sub-
populations show clinically divergent epidemiology. 
 
2.3 Materials and methods 
Data sources / selection criteria 
 Search strategy: a comprehensive literature search using PubMed and Google 
Scholar was performed in English, searching for (‘vivax’ OR ‘benign tertian’) AND 
(‘induced’ OR ‘human’ OR ‘experimental’); more limited searches were performed in 
Dutch, German and French. The citations in these initial papers were examined, and 
from these a large number of non-indexed papers were identified.  
 Data inclusion criteria: malaria-naïve human cases, with defined inoculation dates 
(mosquito infection only; sporozoite injection and blood transfers were excluded), 
explicit symptomatic-only drug treatments, protection from re-infection, and named, 
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traceable stains with defined place of origin. For the incubation period study, only this 
metric was utilized, and not pre-patent periods; for the relapse study, only papers with 
explicit follow-up periods were included. Incubation periods of > 50 days have not 
been included in the exact incubation period analysis due to very small numbers in 
well-defined studies (7 individual cases excluded). 
 
Characteristic Number (%) 
Neurosyphilis / neurotreatment patient 433 (64.0) 
Exact incubation period recorded 460 (68.0) 
Time-to-relapse recorded 320 (47.3) 
Exact incubation and time-to-relapse recorded 104 (15.4) 
Infected with tropical strains 275 (40.6) 
Infected with temperate strains 402 (59.4) 
Infected with New World strains 181 (26.7) 
Infected with Old World strains 496 (73.3) 
Total 677 
Length of follow-up in weeks: mean, (SD) 
[Range] 
82.5, (31.7) [2.0 to 173.0] 
 
Table 1. Study population, historical P. vivax studies.  
Note: Studies conducted ca. 1920-1980. 
 
 Available covariates were extracted from these studies, and the individual records 
were digitized with PlotDigitizer as needed, to create individual case-patient records 
(Huwaldt 2012). Data for the incubation period study consists of 453 patients, 
infected with 11 strains, from 19 studies; data for first relapse include 320 patients, 18 
strains, from 15 studies (see Table 1). Details of the parasite strains included in this 
analysis are shown in Table 2. Age and gender were not recorded for the majority of 
the neurosyphilis patients; all prison volunteers were Caucasian men. Several sources 
had interval censoring, that is, infections were reported as occurring within “month # 
1” or “week # 16” from infection. To facilitate comparisons between studies, reports 
with more specific relapse times were then converted up to the next integer week  
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from infection. Latitude of isolation was determined from the site of isolation in the 
original reports, and coded as a binary variable (dividing at +/- 23.5 degrees S/N) for 
determining tropical and temperate; “New World" includes the Americas, and “Old 
World” consists of Eurasia, Africa and the Pacific, as previously suggested (Li et al. 
2001). 
 
Statistical analysis 
 Statistical analysis was performed using Stata 12.1 (College Station, Texas); all 
tests were two-tailed. Kaplan-Meier analysis was used to examine the unadjusted 
relationship between parasite origin and event times; differences were assessed using 
a log rank test. Multivariate models were used to overcome the limitations of Kaplan-
Meier analyses and to provide adjustment for the impact of neurological treatment 
and other covariates, and to produce hazard ratios to gauge to strength of association. 
The standard Cox proportional hazards model is unable to provide confidence 
intervals for predicted survival times; therefore, more complex models (flexible 
parametric Royston-Parmar models) were used to provide both covariate-adjusted 
hazard ratios (HR) and covariate-adjusted median survival times for sub-populations 
(Royston and Parmar 2002). These models extend Cox methods by adding parameters 
that model the underlying hazard of a disease event, which allows more 
comprehensive predictions to be made. The predicted survival times from this 
analysis have all been made for a neurological treatment-free population, to provide 
estimates that are relevant to natural human infections. Detailed methods can be found 
in Appendix A. 
 
 
 27 
 
Table 2. P. vivax strains included in analysis of geographic variation.  
Note: Temp = temperate; Trop = tropical (see text for definitions). 
 
2.4 Results 
Incubation period 
 The Kaplan-Meier plot of the 461 included case-patients shows a wide separation 
of groups, by tropical/temperate (Figure 3-A) and latitude/hemisphere (Figure 3-C), 
both of which are statistically discernable (tropical/temperate log-rank test for 
equality, 𝜒!  = 131.7, 1 df, p < 0.0001; by region, 𝜒!   = 206.4, 3 df, p < 0.0001) 
 
 
 
 
Strain Place & date of origin Malariotherapy 
(% of total, if Y) 
Zone n 
Chesson  Papua New Guinea, c. 1944 N Trop 145 
Hlebnikovo  Moscow Oblast, 1948 Y (100%) Temp 19 
Holland  Netherlands, c. 1928 Y (100%) Temp 52 
Korea  North Korea, 1953 Y (100%) Temp 21 
Leninabad  Tajikistan, 1950 Y (100%) Temp 33 
Madagascar Madagascar, 1925 Y (100%) Trop 83 
McCoy  Florida, USA, 1931 Y (100%) Temp 70 
Moscow  Moscow, 1950 Y (100%) Temp 55 
NICA  Nicaragua, c. 1970 N Trop 6 
Nahicevan  Azerbaijan, 1937 Y (100%) Temp 5 
Naro-Fominsk  Moscow Oblast, 1946 Y (100%) Temp 21 
Panama  Panama, c. 1970 N Trop 10 
Rjazan  Ryazan, Russia c. 1945 Y (100%) Temp 21 
St. Elizabeth  Southern USA, c. 1925 Y (34.2%) Temp 73 
Salvador I  El Salvador, c. 1970 N Trop 11 
Salvador II  El Salvador, c. 1970 N Trop 11 
South Vietnam Southern Vietnam, c. 1972 N Trop 5 
Vietnam  (North) Northern Vietnam, 1954 Y (100%) Trop 4 
Volgograd  Volgograd, Russia, 1945 Y (100%) Temp 24 
West Pakistan Pakistan, 1968 N Temp 5 
P. vivax multinulatum Central China, 1965 N Temp 3 
Total  64.0%  677 
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Figure 3. Kaplan-Meier and flexible parametric models, incubation period and time-to-
first relapse, historical P. vivax experimental infections. 
Notes: Panel A. Kaplan-Meier estimates for incubation period, temperate/tropical strains.  
Panel B. Kaplan-Meier estimates for time-to-first relapse, temperate/tropical strains. Panel C. 
Kaplan-Meier estimates for incubation period, by region. Panel D. Kaplan-Meier estimates 
for time-to-first relapse, by region. Panel E. Flexible parametric survival model, incubation 
period projected for neurotreatment free populations, by region. Panel F. Flexible parametric 
survival model, time-to-first relapse projected for neurotreatment free populations, by region. 
 
 The combined tropical strains have an unadjusted median incubation period of 12 
days (95% CI: 12 to 12) vs. 15 days (95% CI: 14 to 16) for the temperate. When 
stratified by Old World/New World, the tropical strains remain essentially unchanged, 
but a large separation occurs in the temperate strains, with a median survival times of 
New World, Temperate 14 (95% CI: 14 to 15), and Old World, Temperate 20 (95% 
CI: 19 to 21) days. 
 In the full multivariate model, after adjustment for strain effects and neurological 
treatment status, the parametric survival estimates for the entire population are a 
median of 13.6 days (95% CI: 12.5 to 14.7) (Figure 3-E). The 95th percentile of the 
incubation period is 17.9 days (95% CI: 16.6 to 19.1). Differences are observed for 
the times between all regions, except for the New World tropical/temperate 
categories, which did not achieve significance (p = 0.30) (see Appendix A). The  
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predicted median and 95th percentile survival times are shown in Figure 4. There are 
no significant differences within the confidence intervals for predicted median 
survival times with the exception of Old World Temperate (20.1 (95% CI: 17.8 to 
22.5)); the 95% percentile for temperate strains are significantly longer than tropical 
strains. The hazard ratios for the regions: Old World, Tropical 16.8 (95% CI: 7.6 to 
36.9); New World, Tropical 10.8 (95% CI: 4.6 to 25.2); New World Temperate 7.3 
(95% CI: 3.8 to 14.0); and Old World, Temperate (reference). The case-patients 
infected with Old World tropical strains (the shortest incubation periods) show 16.8 
times (7.6 to 36.9) higher hazard relative to Old World temperate strains (the longest 
time to event). 
 
Figure 4. Median and 95th centile survival times, incubation period in days. 
Note: Flexible parametric survival models, adjusted for neurotreatment status. 
 
Time-to-first relapse 
 The time-to-first relapse for all studies was measured from the reported primary 
infection. The Kaplan-Meir survival curves for the 312 included case-patients show 
large, statistically significant differences by both tropical/temperate (Figure 3-B) and 
latitude/hemisphere (Figure 3-D) (tropical/temperate, log rank test for equality, 𝜒!  = 
61.5, 1 df, p < 0.0001; by regions, 𝜒!   = 145.2, 3 df, p < 0.0001). Comparing the  
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curves in Figure 3-D shows that the two New World categories fall between the 
wider-ranging Old World tropical and temperate categories. In the full multivariate 
model adjusted for strains and neurotreatment status, a distinct separation between the 
hemispheres is observed (Figure 3-F). The estimated total population values from this 
model show a median time-to-relapse of 13.5 weeks (95% CI: 8.9 to 18.1), and a 95th 
percentile of 48.8 weeks (18.2 to 79.3).  
 However, these aggregate values hide substantial heterogeneity in time-to-relapse. 
Both of the Old World categories show shorter time-to-relapse relative to New World 
parasites, with the tropical strains for both hemispheres exhibiting short times relative 
to the corresponding temperate strains, although this difference is not significant in 
the New World (Figure 5).  The median times-to-relapse, in weeks, are: Old World 
Tropical 4.5 (95% CI: 3.2 to 5.7); New World Tropical 26.8 (95% CI: 18.4 to 35.2); 
Old World Temperate 13.7 (95% CI 8.3 to 19.1); and New World Temperate 29.7 
(95% CI 28.3 to 31.1). The corresponding 95th percentile times are: Old World 
Tropical 10.0 weeks (95% CI: 7.2 to 12.9); New World Tropical 60.3 (95% CI: 39.1 
to 81.5); Old World Temperate 30.9 (95% CI: 19.9 to 41.9); and New World 
Temperate 66.8 (95% CI: 59.5 to 74.2). The hazard ratios from the survival models, 
after adjusting for neutrotreatment, are: Old World, Tropical 30.7 (95% CI: 14.1 to 
66.6) (p < 0.001); New World, Tropical 1.2 (95% CI: 0.67 to 2.12) (p = 0.53); Old 
World, Temperate 4.0 (95% CI: 2.1 to 7.6) (p < 0.001); and New, Temperate 
(reference).  
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Figure 5. Median and 95th centile survival times, primary attack to first relapse, in days.  
Note: Flexible parametric survival models, adjusted for neurotreatment status. 
 
Distribution of total relapses 
 The total number of relapses was compared by latitude and hemisphere (see 
Appendix A). A time interval of 48 weeks was chosen to ensure equivalent follow-up 
periods between the regions [Oneway ANOVA, follow-up time by region, F (3, 43) = 
1.07 (p = 0.37)]. The Kolmogorov-Smirnov test for equality of distributions shows 
statistically significant differences between both tropical and temperate strains (p < 
0.00001); and Old World and New World Strains (p = 0.00009). These differences 
remain highly significant when stratified by zones of latitude: Temperate strains, Old 
World vs. New World, (p = 0.00006); and Tropical strains, Old World vs. New 
World: (p < 0.00001).  
 
2.5 Discussion and conclusions 
Comparison with prior estimates 
 Malariologists have made a large number of observations concerning the 
geographic epidemiology of P. vivax (Young et al. 1947, Coatney et al. 1971). 
Malariotherapy treatments initially used a range of local strains, from the UK, the  
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Netherlands, and US, but these were quickly replaced with the Madagascar strain 
among others, which exhibited shorter incubation periods and more reliably produced 
infections (Chernin 1984). A range of estimates have been reported in the literature 
for the incubation period of P. vivax: a mean of 13.88 days (S.D. 3.7); 14 ± 3 days 
after the mosquito bite; 12 to 17 days (mean 15); and a minimum of 8 days, extending 
up to 17 days (Boyd and Kitchen 1937, Baird et al. 2007, Warrell and Gilles 2002, 
Russell 1963). A modern quantitative analysis of malariotherapy data with a single 
strain (Madagascar) provided estimates for the pre-patent period of ~ 10.3 to 16.9 
days (reported to be generally 3 days longer than the incubation period within this 
study) (Glynn and Bradley 1995). After adjustment for strain and neurological status, 
the parametric survival estimates for the population in this study are a median of 13.6 
days (95% CI: 12.5 to 14.7) and the 95th percentile of the incubation period is 17.9 
days (95% CI: 16.6 to 19.1). The minimal differences between the Kaplan-Meier 
estimates and those from the multivariate models for incubation period strongly 
supports earlier opinions that data from malariotherapy are indeed applicable to 
natural infections (Winckel 1941). 
 Similarly, a range of observations has been reported concerning relapse, with 
strain-specific relapse behaviour (Warrell and Gilles 2002). Relative to temperate 
strains, tropical strains are reported to relapse more, have a shorter relapse period of 
17-45 days, with a higher proportion having more than 2 relapses (Baird et al. 2007). 
It has been estimated that tropical strains relapse every 3-4 weeks, whereas temperate 
strains show longer periods between relapses with greater variability (Douglas et al. 
2012). 
 The estimates from this study suggest that prior estimates for time-to-relapse have 
been based primarily on data for Old World tropical strains (4.5 weeks (95% CI: 3.2 
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to 5.7)). The results from the other regions are all significantly longer than earlier 
estimates, with the exception of a single study from El Salvador, which reported a 
median relapse interval of 28 weeks (Mason 1975). The arithmetic median interval for 
all tropical strains (including only exact, non-interval censored times) is 19.5 weeks 
(95% CI: 15.5 to 23.4). The unadjusted Kaplan-Meier estimates, and parametric 
models adjusted for strain and neurological treatment status in the full dataset also 
indicate much longer mean and median times-to-relapse: the parametric survival 
estimates for tropical strains are a median of 17.7 weeks (95% CI: 12.2 to 23.2) and 
mean of 17.2 weeks (95% CI: 10.0 to 24.5). The differences in relapses are striking: 
patients infected with Old World temperate strains have 30.7 times (95% CI: 14.1 to 
66.6) higher hazard to relapse relative to those infected with New World temperate 
strains. The substantial differences between Figures 3-D and 3-F suggest that 
neurological treatment has significant impacts on the course of relapse; therefore 
unadjusted relapses times from malariotherapy should be interpreted with caution. 
 The range of relapses recorded within 48 weeks (for equivalent follow-up) is also 
consistent with prior estimates: tropical strains show a median of 2.6 relapses (95% 
CI 1.9 to 3.3) range (0-9); with temperate having a median of 0.68 (95% CI 0.55 to 
0.80), range (0-6). The total percentage of case-patients with relapses in these data, 
68.5% (95% CI: 64.9 to 71.8) is broadly consistent with previous work that suggests 
about 60% of untreated cases relapse (Warrell and Gilles 2002). 
 The general agreement of prior knowledge of incubation period and number of 
relapses with the results from this study support the conclusion that these patients do 
not represent a substantially different population from natural P. vivax infections. 
However, these aggregate cohort values obscure large regional differences in 
epidemiology. 
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Geographic differences 
 The qualitative impact of geography of the parasites has been long recognized, 
with conspicuous differences in incubation period and latency that have been broadly 
correlated with climatic zones (Warrell and Gilles 2002). However, there have also 
been persistent difficulties in classifying these patterns; some studies suggested two 
different types of temperate strains, North American (St. Elizabeth) and European 
(Netherlands), plus tropical groups (Winckel 1955). Inconsistencies have also been 
noted, including tropical Central American P. vivax strains which showed anomalous 
‘temperate zone’ epidemiology, leading to a suggestion that temperature alone might 
be an insufficient predictor (Contacos et al. 1972). These conflicting observations are 
fully consistent with the results from this study (Figure 3-F), where the most 
noticeable feature is that both New World populations displaying significantly longer 
times-to-relapse than Old World parasites.  
 Our results suggest that the epidemiology of P. vivax infection has been occluded 
by inherent differences between sub-populations, and that both hemisphere and 
latitude are strong drivers of clinical presentation and epidemiology. This strongly 
suggests that current paradigms for P. vivax clinical follow-up and surveillance may 
be based on erroneous assumptions. Malaria should not be discounted as a diagnosis 
even in the presence of long incubation periods, and the geographic origin of the 
parasite has critical impacts on clinical presentation and should not be ignored in case 
histories.  
 Our results show that the mean incubation period of Eurasian temperate strains is 
statistically, and clinically significantly longer than generally considered. This, plus 
the inherently longer extrinsic incubation period for Old World temperate strains 
suggests that an active surveillance period of 31 days after potential exposure is the 
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minimum necessary to capture the 95th percentile of new cases. However, this 
potential surveillance burden is balanced by a shorter median time-to-relapse for these 
parasites relative to New World strains. 
 These three sets of independent measures (incubation period, time-to-first-relapse, 
and distribution of total relapses) across the entire course of illness all suggest that P. 
vivax should not be considered a single parasite, but is in fact several discrete, and 
clinically distinct populations with unique and measurable characteristics. These data, 
plus the prior entomological and molecular evidence, support the delineation of sub-
species within the range of the parasite: P. vivax vivax within the Eastern hemisphere, 
and P. vivax collinsi within the Western. This conclusion is supported by a recently 
published phylogenetic analysis of global P. vivax strains, which shows both high 
diversity and clustering of isolates by hemispheres (Neafsey et al. 2012). 
 
Public health impacts 
 Parasite origin has been shown to have large impacts on both prophylaxis and 
treatment: while Korean-strain infections respond to standard dosing of primaquine, 
even higher doses did not fully suppress strains from New Guinea (Chesson), and the 
Chesson strain required twice the dosing of quinine base relative to a North American 
strain (McCoy) (World Health Organization 1969). A related study on the impact of 
primaquine also found large regional effects, and additionally, that Thai strains were 
more likely to relapse, and required higher doses to suppress relapses relative to 
parasites of Indian or Brazilian origin (Goller et al. 2007). The impact of parasite 
population differences should be considered in the planning and analysis of 
interventional trials, and in potential vaccine trials. 
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 A recent analysis of malaria imported into the US and Israel found that a large 
proportion of cases exhibited long-latency: of 721 P. vivax cases with 
insufficient/non-existent prophylaxis, 46.5% (95% CI: 42.8 to 50.2%) had a delayed 
incubation period of > 2 months, whereas this was observed in 80.0% (95% CI: 77.0 
to 82.8%) of travellers with sufficient prophylaxis (authors’ calculations, from 
(Schwartz et al. 2003)). However, no information is provided about the geographic 
source of these parasites, and the date of exposure is assumed to be the end of travel 
period, making exact calculation of incubation period impossible. The results from 
our study are broadly consistent with these values: 31.3% (95% CI: 26.2 to 36.6%) of 
cases-patients in the time-to-relapse data have an incubation period of greater than 8 
weeks. The comparability of these drug-free populations suggests long-term stability 
in the global parasite populations, and also supports the relevance of these historical 
challenge studies for modern surveillance programs. Finally, the potential for 
prolonged incubation due to prophylaxis suggests that the estimates from our analysis 
should be considered as minimum values for travellers with adequate antimalarial 
drug compliance. 
 
Conclusions 
 Control and elimination programs for P. vivax should be reconsidered in light of 
these findings. Two major stumbling blocks of the First Global Malaria Eradication 
Campaign (1955-1972) were an assumption that control methods could be universally 
applied, and combined personnel and funding fatigue for continued surveillance at 
increasingly lower levels of infection (Nájera 1999). Addressing these issues in the 
current elimination campaign will require detailed elucidation of differences in 
pharmacodynamics among parasite sub-populations, and locale-specific 
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epidemiology, including estimation of incubation periods and time-to-relapse to 
maximize surveillance efficiency.  
 Our results suggest that considerable complexity among P. vivax populations has 
been obscured by data aggregation; however, these divisions appear along defined 
geographic gradients. The long time interval of these studies (1920’s to 1980’s) 
implies relatively stable parasite populations; however the impact of greatly increased 
airplane travel and migration should be explored. The diversity of study sites and 
investigators included in this study strongly suggests the observed epidemiological 
variations are not due to differences in study protocols or vector species. 
 The existence of sub-populations along Eastern/Western hemispheres allows 
conflicting historical and epidemiological data to be formulated into a consistent and 
coherent picture, especially with the incorporation of phylogenetic approaches. 
Additionally, the parasite origin should be considered in drug prophylaxis and 
treatment, and the pharmacokinetic differences in the parasites should be more fully 
elucidated.  
 
‘Local malaria problems must be solved largely on the basis of local data. It is 
rarely safe to assume that the variables in one area will behave in the same way as 
they do in another area, however closely the two regions may seem to resemble 
each other in topography and climate. Large sums of money have been wasted in 
attempted malaria control when malariologists have forgotten this fundamental 
fact.’ 
  - Paul F. Wallace, 1946 (Russell et al. 1946). 
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Chapter 3: Re-assessing the relationship between sporozoite dose and 
incubation period on Plasmodium vivax malaria: a systematic re-
analysis 
 
This work has been published as: Lover AA, Coker RJ (2014), Re-assessing 
the relationship between sporozoite dose and incubation period on 
Plasmodium vivax malaria: a systematic re-analysis. Parasitology 
(Cambridge) 141(6), 859-868. 
 
3.1 Abstract 
 Infections with the malaria parasite Plasmodium vivax are noteworthy for 
potentially very long incubation periods (6–9 months), which present a major barrier 
to disease elimination. Increased sporozoite challenge has been reported to be 
associated with both shorter incubation and pre-patent periods in a range of human 
challenge studies. However, this evidence base has scant empirical foundation, as 
these historical analyses were limited by available analytic methods, and provides no 
quantitative estimates of effect size. Following a comprehensive literature search, we 
re-analysed all identified studies using survival and/or logistic models plus 
contingency tables.   
 We have found very weak evidence for dose-dependence at entomologically 
plausible inocula levels. These results strongly suggest that sporozoite dosage is not 
an important driver of long-latency. Evidence presented suggests that parasite strain 
and vector species have quantitatively greater impacts, and the potential existence of a 
dose threshold for human dose-response to sporozoites. Greater consideration of the 
complex interplay between these aspects of vectors and parasites are important for 
human challenge experiments, vaccine trials, and epidemiology towards global 
malaria elimination. 
 39 
3.2 Introduction 
 Malaria caused by Plasmodium vivax, after decades of research neglect, is being 
re-assessed as a major contributor to morbidity and mortality in the widespread 
regions where it is endemic (Price et al. 2007, Galinski and Barnwell 2008). 
However, large gaps still exist in knowledge of the epidemiology, entomology, and 
ecology of this parasite (Mueller et al. 2009, Gething et al. 2012). One of these gaps 
is the phenomenon of extended incubation periods (> 28 weeks) (Warrell and Gilles 
2002). These phenotypes have been observed in modern parasite strains from diverse 
global settings including Brazil and the Korean peninsula (Brasil et al. 2011, Kim et 
al. 2013) and antimalarial drug prophylaxis has also been implicated in prolonged 
latency (Schwartz et al. 2003). The biological basis of delayed onset infections after 
sporozoite inoculation remains unclear; whether the persisting parasites are 
hypnozoites, quiescent merozoites or both is unknown (Markus 2012). Persistent and 
infective dermal sporozoites have also been suggested (Guilbride et al. 2012, Ménard 
et al. 2013). 
 The incubation period is a key parameter in epidemiological and clinical studies; 
in malaria, it is defined as the time from exposure to infected anopheline vectors to 
febrile illness. The pre-patent period is similarly calculated to the time when parasites 
are first visible in the peripheral blood. Gaps in these areas have been highlighted as 
key research needs for P. vivax human vaccine development (Targett et al. 2013). 
 Historical human experimental challenges during malariotherapy for terminal 
neurosyphilis (1920s–1950s) and prison volunteer experiments for antimalarial 
prophylaxis suggested an inverse relationship between the size of sporozoite inocula 
and time-to-infection; modern reviews have supported this view (Krotoski et al. 1986, 
Glynn 1994, White 2011, Vanderberg 2014).  
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 Specifically, it has been reported that small sporozoite doses (10–100 sporozoites) 
of P. vivax strains isolated from temperate regions resulted in the primary attack 
generally being delayed for 9–10 months or longer, whereas illness occurred after a 
‘normal’ incubation period of about two weeks (White 2011) when larger inocula (≥ 
1000 sporozoites) were used. Conversely, for tropical parasite strains in these 
historical studies, no relationship between sporozoite doses and the latent period was 
observed.   
 However, there is also considerable ambiguity in relation to dose-dependence in 
the literature; some authors suggest no differences by latitude of parasite origin, with 
dose dependence of time-to-infection being a general feature of P. vivax (Vanderberg 
2014). Pampana reported that long-latency was due to small inocula, but also quoted 
Russian researchers who described four strains that invariably showed long-latency 
(Pampana 1969). Other researchers reported that the length of incubation of a North 
Korean strain was dependant on the number of mosquito bites (Tiburskaja and 
Vrublevskaja 1977). Finally, recent research has suggested that parasite strain itself 
may independently influence incubation period (Herrera et al. 2009). 
 These historical studies utilized analytical methods that were very limited and 
inappropriate for time-to-event data, including simple linear regressions, differences 
in means between groups, or qualitative reporting of trends between groups. For 
example, in foundational work James reported that in a large series of 700+ cases 
analysed by linear regression, the incubation period was inversely correlated with the 
number of mosquitoes biting (James 1931); other researchers suggested an inverse 
relationship using mosquito-transmitted St. Elizabeth strain infections based on a 
visual examination of the trend writing, “Correlation is apparent and all of the 3 
greatly delayed primary attacks occurred after relatively small inocula” (Coatney, 
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Cooper, Ruhe, et al. 1950). These studies, while limited by experimental design and 
reporting, form the core evidence for the alleged dose-dependent basis of long-latency 
in both experimental and natural P. vivax infections, but their validity has heretofore 
not been formally investigated. 
Inherent issues with all methods of quantifying malaria parasite doses have 
been previously reviewed (Glynn 1994). Briefly, the use of bite-based metrics 
assumes that all mosquitoes inject the same dose.  The use of qualitative gland 
infection metrics is even more problematic, as a count of 6 ‘pluses’ could be a single 
heavily infective, 2 moderately infective, or 3 sparsely infective bites; with larger 
values of 20–30 ‘pluses’ this becomes even more uncertain. Lastly, even 
‘quantitative’ doses are estimates; not all sporozoites may be viable, and dosing may 
be compromised by adhesion to glass syringes, among other experimental issues 
(Glynn 1994). 
In light of the severe limitations in these analyses, we sought to both critically 
review and to re-analyse these historical studies using appropriate statistical methods, 
with the intent to provide a solid evidence base for associations between sporozoite 
dosage and incubation/pre-patent period in P. vivax infections. 
 
3.3 Methods 
Data inclusion  
 A comprehensive search was performed in Medline and Google Scholar, using 
[“vivax” AND (“sporozoite” OR “inoculation”) AND (“latent” OR “incubation” OR 
“pre-patent”)] to identify all publications and grey literature reports that examined the 
relationship between sporozoite exposure and either incubation or pre-patent period. 
The references in these papers were then consulted, and un-indexed papers were 
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identified.  Inclusion criteria were malaria-naïve subjects (except for a set of studies 
in non-human primates); explicit follow-up without chance of re-infection; and 
inclusion of only primary infections (‘latencies’ due to presumed hypnozoite 
activation were not included). Exclusion criteria were poorly documented studies with 
insufficient experimental detail. Tropical and temperate strains were separated at 
27.5° N/S, based on the reported origin of the parasites. All available covariates were 
extracted for multivariate analysis.  
 
Analysis  
 A full meta-analysis was not possible due to wide variations in reported dose 
measurements, times-to-events, and extensive data aggregation in many reports. 
Three complementary sets of analyses are presented: those from studies that reported 
semi-quantitative biting-based exposure metrics; quantitative inoculations in humans; 
and finally quantitative inoculations in non-human primate models. Contingency 
tables (𝜒! tests using Fisher’s exact test) were utilized to assess if any relationship 
exists between dose and incubation period or pre-patent period, but this analysis was 
unable to assess the direction or magnitude of response. Because of these limitations, 
after examination of Kaplan-Meier plots we used Cox proportional hazard models to 
address both of these issues.  
 Each of the identified studies was analysed with the optimal methods considering 
the available data; for aggregated data, only contingency tables could be analysed. 
These tables were calculated for all studies to allow comparison between them. For 
more detailed reports, both the log-rank test for trend in dose categories, and hazard 
ratios (HR) from Cox survival models are presented with survival times, with sub-
group analyses where possible. In this study, survival model analyses are focused on 
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consideration of the time span from inoculation to all observed (clinical or 
parasitological) infections. Each of the exposure categories has a rate of progression 
to infection within the time interval of clinical follow-up (the ‘hazard rate’); the 
hazard ratio follows as the ratio of any of these rates. A hazard ratio of 1.50 can be 
interpreted as having 1.5 times greater likelihood of presenting with infection at all 
time points throughout the study, relative to the reference (low-dose) group. These 
models allow for adjustment of covariates, and provide measures of effect size and 
associated confidence intervals. Lastly, for one study logistic regression was also 
utilized to examine a binary outcome of clinical infection. 
 We used the exposure categories presented in the original reports where possible; 
doses reported as continuous values were divided into tertiles for consistent analysis 
and event times were also divided into tertiles for contingency table analysis. In 
studies with non-explicit follow-up, unsuccessful infections were censored one day 
after the final reported infection (Collins et al. 1994). Cox survival models were 
tested for proportional hazard violations using Schoenfeld residuals; logistic 
regression model fit was assessed using the le Cessie-van Houwelingen-Copas-
Hosmer unweighted sum of squares test (Hosmer et al. 1997). Statistical analysis was 
performed using Stata 12.1 (College Station, Texas, USA) and all tests were two-
tailed with α = 0.05. 
 
3.4 Results 
 The majority of studies utilizing bite-based metrics showed no association 
between the number of infected bites and the incubation/pre-patent period in either 
contingency table or survival model analysis (Tables 3 and 4). We will therefore 
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focus on those that showed evidence of statistically significant effects of dose on 
time-to-infection. 
 Contingency table analysis of studies with the tropical Chesson strain (Table 3, 
study III) used a dose metric of ‘pluses’ to grade the salivary gland estimated 
sporozoite density in the infecting mosquitoes on a qualitative scale from 1 to 6. We 
found a significant association (p < 0.001) between the tertiles of prepatent period and 
tertiles of the reported ‘mean pluses’; this remained unchanged when analysed for all 
explicit dose categories (mean pluses of 22, 25, 27, 29, 30, 32, and 36; range of 12–
36). This range of ‘pluses’ would indicate 2 to 36 bites (Whorton et al. 1947). 
 A study using the temperate St. Elizabeth strain  (Table 3, study IV) showed 
significant dose-dependence in both contingency table and survival analyses. In Cox 
models, relative to 11-20 pluses, a dose of 21–30 pluses had a hazard ratio of 5.7 
(95% CI 1.6 to 19.8; p = 0.007), and a dose of 31–40 pluses (~ 3–10 infected bites) 
led to an hazard ratio of 8.4 (95% CI 2.5 to 28.7; p = 0.001) (Coatney, Cooper, Ruhe, 
et al. 1950). That is, at all times throughout the study, the higher dose groups had a 
5.7 and 8.4 times greater likelihood respectively of presenting with infection relative 
to the lowest-dose group. The relationship between dose classes and tertiles of the 
pre-patent period was also significant in contingency table analysis (p < 0.001). 
Analysis by contingency tables of long-term malariotherapy studies that used a North 
Korean strain (Table 3, study VI) showed evidence of dose-dependence for doses of 
up to 23 bites (p = 0.012); however, when limited to dose categories < 11 bites, there 
was no evidence for an association between bites and the length of incubation periods 
(p = 0.256).   
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Study N Strain Dose 
metric 
Hazard 
ratio 
95% CI for 
hazard ratio 
p for 
hazard 
ratio 
p value for 𝛘𝟐 test, dose 
metric vs. 
time-to-
event 
(tertiles) 
Reference 
I.  
 
13 Southern 
US 
1 bite 
2–5 bites 
6–10 bites 
ref. 
0.30 
0.41 
- 
0.066 to 1.41 
0.093 to 1.79 
- 
0.128 
0.235 
0.259  † (Mayne 1933) 
II.  78 Dutch 3–5 bites 
6–10 bites 
11–20 bites 
21–30 bites 
> 30 bites 
- - - Reported as 
Long/short, 
0.250 † 
(Swellengrebel 
and De Buck 
1938, Verhave 
2013) 
III.  
 
87 
 
Chesson 22–27 
mean 
pluses 
29–30 
mean 
pluses 
32–36 
mean 
pluses 
- - - < 0.001 # (Whorton et al. 1947) 
IV.  
 
53 St. 
Elizabeth 
11–20 
pluses 
21–30 
pluses 
31–40 
pluses 
ref. 
5.65 
8.41 
- 
1.61 to 19.80 
2.47 to 28.67 
- 
0.007 
0.001 
< 0.001 # (Coatney, 
Cooper, Ruhe, et 
al. 1950) 
 
V.  
 
15 Chesson 2 pluses 
3 pluses 
4 pluses 
ref. 
0.79 
2.93 
- 
0.16 to 3.95 
0.80 to 10.73 
- 
0.78 
0.10 
0.189 # (Coatney, 
Cooper, and 
Young 1950) 
 
VI.  
 
77 
 
 
 
subset 
(n = 67) 
 
N. Korean 1–2 bites 
3–5 bites 
6–23 bites 
 
1–2 bites 
3–4 bites 
5–10 bites  
 - - Reported as 
Long/short,  
0.012  † 
 
Long/short 
0.256  † 
(Tiburskaja and 
Vrublevskaja 
1977) 
VII.  
 
24 Yunnan 1–2 bites 
3–5 bites 
7–10 bites  
ref. 
2.27 
4.00 
- 
0.74 to 6.95 
1.23 to 12.96  
- 
0.152 
0.021 
0.038  † (Yang 1996) 
VIII.  
 
17 Venezuela 2–4 bites 
6–7 bites  
8–10 bites 
ref. 
1.67 
1.69 
- 
0.47 to 5.98 
0.45 to 6.30 
- 
0.43 
0.43 
0.678 # (Herrera et al. 
2009) 
IX.  
 
16 Venezuela 2 bites 
3 bites  
4 bites 
ref. 
2.73 
1.74 
- 
0.76 to 9.81 
0.20 to 14.94 
- 
0.12 
0.61 
0.249 # (Herrera et al. 
2011) 
 
Table 3. Analysis of sporozoite effects in historical human P. vivax malaria challenge 
studies; vector bite-based exposures.  
 (Studies I – IX), assess the relationship between sporozoite dose and pre-patent or incubation 
period (bold-faced entries are significant with p < 0.05). Notes: ‘Pluses’ refers to the grand 
total of the estimated sporozoite density (qualitative grading from 1 to either 4 or 6, 
depending on the study, see text) for the infected mosquito or mosquitoes used in challenge, 
per volunteer.  For χ!  tests not using tertiles, ‘short’ refers to incubation periods of less than 8 
weeks, and ‘long’ as anything longer (generally, 6–9 months).  
Study end point: † = incubation period; # = prepatent period. 
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 More recent experimental infections with a P. vivax strain from Yunnan (Table 3, 
study VII) showed no significant difference between 1–2 bites (reference) and 3–5 
bites (HR = 2.3, 95% CI 0.74 to 7.0; p = 0.152), but there was evidence for dose-
dependence at higher doses of 7–10 bites (HR = 4.0, 95% CI 1.2 to 13.0; p = 0.021). 
Finally, the overall χ! test and the log-rank test for trend for an association between 
bites and incubation period were both marginally significant (p = 0.038 and p = 
0.032).  
 Analysis of data from a large series of studies reporting discrete (integer) bite 
exposures is presented in Table 4 (study Xa). Log-rank test for trend in survival 
curves from Kaplan-Meier analysis showed no difference between category doses of 
1–5 bites inclusive (p = 0.486) in the incubation period; however, inclusion of the full 
data (reported as 1 to 10 individually and 11-20; 21-30; 31-40 bites) suggested a 
significant difference in incubation period (p < 0.0001). In a multivariate Cox model 
adjusted for mosquito batch oöcyst grading (as reported in the original publication, as 
either: all in the infecting lot having < 50 sporozoites; or at least one in infecting lot 
having > 100 sporozoites) while there were no significant differences in the range of 
doses from a single bite to five inclusive, statistically significant differences in the 
hazard ratios were apparent from six infected bites onwards. The highest exposure 
category of 31-40 infected bites had an adjusted hazard ratio of 23.9 (95% CI: 3.1 to 
186.8; p = 0.002). These results were consistent with contingency table analysis using 
all the reported dose groups (p < 0.001), while analysis of five bites and below did not 
show a significant association with incubation period (p = 0.098).  
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Risk factor Value Hazard 
ratio 
95% CI for 
hazard ratio 
p for hazard 
ratio 
p for 𝛘𝟐 test, tertiles 
of incubation period 
Infected 
mosquito 
biting dose 
1 ref. - - 1 to 31–40 bites 
 < 0.001 
1 to 5 bites 
0.098 
 2 0.99 0.54 to 1.79 0.964  
 3 0.75 0.46 to 1.21 0.236  
 4 1.13 0.66 to 1.93 0.669  
 5 1.29 0.75 to 2.22 0.366  
 6 2.26 1.33 to 3.84 0.002  
 7 1.17 0.67 to 2.07 0.576  
 8 2.23 1.34 to 3.70 0.002  
 9 2.01 1.09 to 3.68 0.025  
 10 1.76 0.91 to 3.39 0.093  
 11–20 2.02 1.12 to 3.63 0.019  
 21–30 1.38 0.42 to 4.57 0.590  
 31–40 23.92 3.07 to 186.78 0.002  
Mosquito 
batch oöcyst 
grading 
All in lot < 50 
sporozoites 
ref. - -  
 At least one in 
lot  > 100 
sporozoites 
1.41 1.06 to 1.89 0.019  
 
Table 4. Analysis of sporozoite effects in historical human P. vivax malaria challenge 
studies; strains from the Southern US.  
(Study Xa), to assess the relationship between sporozoite dose and incubation period (bold-
faced entries are significant with p < 0.05) (N = 261). Source: (Boyd 1940). 
 
 Analysis of the most rigorous experiments identified, which used quantitative 
intravenous/intradermal sporozoite dosing, is shown in Table 5 (studies XI and XII).   
 The dose of 10,000 sporozoites failed due to experimental issues in the North 
Korean strain study and was not reported by the original authors, and the dose of 
100,000 was not included for the Chesson strain. The two highest doses of 10,000 and 
100,000 have been combined for analysis after testing for heterogeneity of effect. 
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Risk factor Value Hazard 
ratio 
95% CI for 
hazard ratio 
p for 
hazard 
ratio 
𝛘𝟐  test, 
tertiles of 
prepatent 
period, 
overall 
𝛘𝟐 test, tertiles 
of prepatent 
period,  
Korean only 
𝛘𝟐 test, 
tertiles of 
prepatent 
period, 
Chesson only 
Estimated 
Sporozoite Dose 
10 ref. - -    
 100 1.10 0.36 to 3.33 0.863    
 1,000 3.59 1.19 to 10.79 0.023 10 to 1,000 
p = 0.846 
10 to 1,000 
p = 1.00 
10 to 1,000 
p = 0.444 
 10,000 / 
100,000 
68.54 7.20 to 651.79 < 0.001 10 to 100,000 
p = 0.081 
10 to 100,000 
p = 0.014 
10 to 10,000 
p = 0.491 
Parasite strain N. Korean ref. - -    
 Chesson 49.62 6.01 to 409.16 < 0.001    
 
Table 5. Cox model analysis of sporozoite effects in historical human P. vivax malaria 
challenge studies; quantitative sporozoite dosing.  
Notes: (Studies XI and XII) Contingency table and survival model analysis of historical 
human to assess the relationship between sporozoite dose and pre-patent period (bold-face 
entries are significant with p < 0.05) (N = 36). Source: (Shute et al. 1976, Ungureanu et 
al. 1976). 
 
Risk factor Value Incidence 
rate ratio (IRR)  
95% CI 
 for IRR  
p for  
IRR 
Estimated Sporozoite Dose 10 ref. - - 
 100 0.96 0.32 to 2.86 0.941 
 1,000 2.62 0.92 to 7.50 0.071 
 10,000 / 
100,000 
13.87 4.84 to 39.72 < 0.001 
Parasite strain N. Korean ref. - - 
 Chesson 39.37 10.04 to 85.96 < 0.001 
 
Table 6. Poisson model analysis of sporozoite effects in historical human P. vivax 
malaria challenge studies, quantitative sporozoite dosing.   
Notes: as in Table 5. 
 
Kaplan-Meier curves for these experiments are shown in Figure 6. The two highest 
doses are evident at the far left, with lower doses tapering out to longer time intervals. 
The log-rank test for trend among doses was marginally significant in the full dataset 
(p = 0.03); inclusion of the lowest three doses (10, 100 and 1000) was significant for 
the Korean strain (p = 0.008), but not for the Chesson strain (p = 0.120).  
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Figure 6. Kaplan-Meier plot for the relationship between prepatent period and 
quantitative sporozoite doses in human P. vivax infections. 
Note: (N = 36) (Shute et al. 1976, Ungureanu et al. 1976). 
  
 In multivariate Cox survival models adjusted for parasite strain with 10 
sporozoites as the references, doses of 100 sporozoites showed no significant impact 
on the pre-patent period, with an hazard ratio = 1.1 (95% CI: 0.36 to 3.3; p = 0.863); 
dosing with 1,000 sporozoites showed an increased HR of 3.6 (95% CI: 1.2 to 10.8; p 
= 0.023); and a dose of 10,000 / 100,000 sporozoites showed a significant effect, with 
an HR = 68.5 (95% CI: 7.2 to 651.8; p < 0.001). Parasite strain itself was significant 
in this analysis: with the North Korean strain as the reference, the tropical Chesson 
strain showed an HR of 49.6 (95% CI: 6.0 to 409.2; p < 0.001). That is, at all time 
points, case-patients infected with the Chesson strain had 49.6 times greater risk of 
presenting with infection relative to those infected with the North Korean strain.  
 This Cox model analysis was complemented with a parallel Poisson regression 
analysis, split at each failure time (Table 6), which showed consistent estimates,  
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except that the 1,000 sporozoite dosage became not significant (IRR = 2.63; 95% CI 
0.92-7.50, p = 0.071). When analysed using contingency tables, there was no 
evidence for a relationship between dose and time-to-event, including the highest 
dosages; the results were unchanged with inclusion of only the Chesson strain. 
Analysis of the North Korean strain alone in contingency tables showed no effect with 
analysis of the 10 to 1,000 doses (p = 1.00), but a significant effect was evident with 
inclusion of the full range of up to 100,000 sporozoites (p = 0.014).  
 Analysis of data from a series of experiments carried out over several years using 
non-human primates with the US CDC ‘Salvador I’ P. vivax strain is shown in Table 
7 (studies XIII–XV). The log-rank test for trend in unadjusted Kaplan-Meier analysis 
with the full dosing arms (which ranges from 1,000 to 2.4 million sporozoites) was 
significant (p = 0.011), but not for doses ≤ 10,000 (p = 0.083) or for doses ≤ 100,0000 
sporozoites (p = 0.500). In the full Cox multivariate model after adjustment for 
primate host species, previous malaria infections in individual non-human primates, 
and sporozoite vector source, with 1,000 sporozoites as the references, doses of  > 
1,000 to 75,000 showed an adjusted HR of 0.60 (95% CI: 0.25 to 1.4; p = 0.101), and 
doses from > 75,000 to 2.4 million showed an HR of 2.2 (95% CI: 1.1 to 4.3; p = 
0.029).   
 Examination of the anopheline source of the sporozoites shows that relative to 
those from An. stephensi, those harvested from An. freeborni had an adjusted HR of 
12.5 (95% CI: 2.6 to 60.4, p = 0.002), while all other vector sources were not 
significant. In contingency table analysis, no association was found between tertiles of 
dose and prepatent period (p = 0.065), and there was also no evidence of association 
between the 1,000 and > 1,000 to 10,000 sporozoites dose categories and tertiles of 
event times (p = 0.29). All of these results were unchanged if only the larger sub-
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population of Saimiri monkeys (n = 65) was included; evidence has suggested that 
these primate species react differently to infection (Collins 2002). 
 
Risk factor Value Hazard ratio 95% CI for 
hazard ratio 
p value for 
hazard ratio 
𝛘𝟐 test, 
tertiles of 
prepatent period 
Estimated 
Sporozoite Dose 
1,000 ref. - - Tertiles of dose, 
p = 0.065 
 > 1,000 to 75,000 0.60 0.25 to 1.43 0.101  
  > 75,000 to 2.4 million 2.16 1.08 to 4.30 0.029 1000 dose versus  
> 1000  
p =  0.290 
Anopheles 
species 
An. stephensi ref. - -  
 An. gambiae 1.26 0.13 to 12.46 0.841  
 An. dirus 2.12 0.86 to 5.55 0.101  
 An. freeborni 12.45 2.57 to 60.38 0.002  
 An. stephensi / dirus 1.60 0.58 to 4.45 0.364  
 
Table 7. Analysis of sporozoite effects in P. vivax malaria challenge studies in 
splenectomised Saimiri and Aotus non-human primate models. 
Notes: (Studies XIII – XV), assessing the relationship between sporozoite dose and 
incubation period (bold-face entries are significant with p < 0.05) (N = 105). 
US-CDC Salvador I strain used; models adjusted for primate host species and previous 
experimental malaria infections in individual non-human primates. 
Source (Collins et al. 1988, 1994, 1996). 
 
 Finally, these survival analyses were complemented with a different series of 
studies from the same publication as study Xa (data not shown; study Xb), examining 
the number of ‘takes;’ that is, bites from an infected vector which produced an 
infection (time span not specified) among 394 inoculations (Boyd 1940). Logistic 
regression was utilized to examine the relationship between the number of infected 
mosquito bites and proportion of exposures producing an infection. Mosquito dose 
was not significantly associated with progression to infection when measured as either 
discrete exposure categories (1 to 10 individually and 11–20; 21–30; 31–40; all p > 
0.06) or for biting dose as a continuous variable (using the mid-point of the higher 
categories; p = 0.88). 
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3.5 Discussion 
Biologically plausible exposure to sporozoites  
 A crucial aspect of these historical studies that has not been previously considered 
is the plausible range of exposure to sporozoites under field conditions. Beyond 
informing experimental studies, these historical studies also serve as the basis for 
understanding natural infections (White 2011). A key measure of malaria exposure in 
field settings is the entomological inoculation rate (EIR, number of Plasmodium-
infective mosquito bites per person per time period). The highest monthly P. vivax-
specific EIRs during high transmission seasons we are aware of are 14.5 from 
Ethiopia (Animut et al. 2013); 44.6 in Sri Lanka; and 46.8 from Thailand [authors’ 
calculations from hourly rates reported in (Ramasamy et al. 1992, Rattanarithikul et 
al. 1996)]. 
 Studies using P. falciparum have estimated the inocula of sporozoites per 
mosquito bite, with a median of 15 sporozoites (range 0–978) in three different 
studies reviewed (Rosenberg 2008); remarkably similar estimates have been obtained 
with multiple rodent malarias (Frischknecht et al. 2004, Medica and Sinnis 2005, Jin 
et al. 2007).  
 Taken together, these suggest that while the absolute maximum exposures under 
natural conditions (assuming maxima of 2 bites per night and inocula of 978 
sporozoites) are ~ 2,000 sporozoites, likely exposures are less than 100 sporozoites. 
Historical work was predicated on vastly higher inocula; for example, 500 bites was 
assumed to inoculate ~ six million sporozoites or 12,000 per bite (Shute et al. 1976).  
 
Impact of sporozoite dose on incubation/prepatent periods  
 A summary of results from our analysis is presented in Table 8, with low dose 
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defined as exposures with entomological plausibility and includes doses of ≤ 5 
infective bites, or ~ 1,000 sporozoites; while these values are not strictly comparable, 
they likely represent similar levels of exposure. 
 
Study N Strain type Dose metric Evidence for 
dose-dependency, 
High dose 
Evidence for 
dose-dependency, 
Low dose 
Reference 
I 13 Temperate bites No No (Mayne 1933) 
II 78 Temperate bites No No (Swellengrebel and 
De Buck 1938, 
Verhave 2013) 
III 87 Tropical mean ‘pluses’ YES - (Whorton et al. 1947) 
IV  53 Temperate ‘pluses’ YES - (Coatney, Cooper, 
Ruhe, et al. 1950) 
V 15 Tropical ‘pluses’ No No (Coatney, Cooper, 
and Young 1950) 
VI 84 Temperate bites YES No (Tiburskaja and 
Vrublevskaja 1977) 
VII 24 Tropical or 
Subtropical 
bites YES No (Yang 1996) 
VIII  17 Tropical bites No No (Herrera et al. 2009) 
IX  16 Tropical bites - No (Herrera et al. 2011) 
Xa  261 Tropical bites YES No (Boyd 1940) 
Xb  394 Tropical bites No No (Boyd 1940) 
XI–
XII  
36 Temperate 
and Tropical 
quantitative 
sporozoites 
YES 
(Temperate only) 
YES (Shute et al. 1976, 
Ungureanu et al. 
1976). 
XIII–
XV  
103 Tropical quantitative 
sporozoites 
YES - (Collins et al. 1988, 
1994, 1996). 
 
Table 8. Summary of evidence for association between sporozoite dose and incubation 
or prepatent period in P. vivax challenge studies. 
Notes: ‘Low’ dose refers to ≤ 5 infected bites or ~ 1,000 sporozoites; ‘High’ dose is any 
greater exposure. ‘Pluses’ refers to the grand total of the estimated sporozoite density 
(qualitative grading from 1 to either 4 or 6, depending on the study) for the infected mosquito 
or mosquitoes used in challenge, per volunteer. 
 
 The studies that show strong evidence for an inverse dose-dependence utilize 
uncertain ‘plus’ metrics that correspond to very high sporozoite exposure: the highest 
exposures in studies III and IV corresponded to 10–40 and 32–36 bites respectively 
(Whorton et al. 1947, Coatney, Cooper, Ruhe, et al. 1950). A similar trend is 
observed in studies XIII-XV, with only doses of > 75,000–2.4 million sporozoites 
having a significant inverse relationship with incubation period. 
 The quantitative dosing experiments in studies XI/XII suggest dose-response: the 
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effects of dosing at 1,000 sporozoites were significant relative to 10 or 100, and the 
combined 10,000/100,000 dose was highly significant. However, when examined by 
strains individually, the Chesson strain showed no evidence of dose-dependence in 
any of our analyses. The Korean strain also showed no dose-dependent effect at 100 
sporozoites relative to 10; doses of 1,000 and higher were associated with shorter pre-
patent periods. However, as likely natural inocula lie in the range from zero to ~ 
1,000 sporozoites, and there were no experimental challenge doses between 100 and 
1000, it is unclear what the relevance of these data are to natural P. vivax infections. 
 The second major limitation in these data is that challenges in studies XI/XII 
utilized both intradermal and intravenous dosing; however, only aggregated data was 
reported. These routes have been shown to have divergent infectivity in experimental 
human P. falciparum infections (Sheehy et al. 2013). Additionally, the non-
randomized nature of treatment arms, and uncertain inclusion/exclusion criteria 
suggest that we cannot discount the possibility that these findings were due to chance. 
 The studies included in this analysis were powered from 0.5–0.96 to detect a 
minimum hazard ratio of 2.0 for dose tertiles. The smallest study reported to have 
acceptable power of 0.83 in survival models was study VII (N = 24); the combined 
quantitative dosing experiment (XI /XII; N = 36) was adequately powered at 0.96. 
The very large confidence intervals for the hazard ratios in several of the analyses 
(e.g. studies X, and XI/XII; Tables 3, 5 and 6) reflect the limited number of subjects 
per strata; however, the lower bounds of these CIs represent a lower limit of effect 
size for significant factors. 
 Our results suggest that the general theory of dose-dependence has exceedingly 
limited statistical support that does not meet modern standards of evidence. While 
broad dose-dependence was found in a subset of the studies, experimental details and 
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the biologically implausible doses utilized make even these results highly suspect. 
 
Threshold effects 
 Our analysis of data from studies VI and X (Tables 3 and 4) suggests that 
mosquito challenge of ~ five bites may represent a fundamentally different biological 
response from greater sporozoite exposure (Boyd 1940, Tiburskaja and Vrublevskaja 
1977). At doses lower than this threshold, there was no evidence of any dose-
response, but a clear inflection point occurred at higher doses, where a dose-
dependent response is apparent. Additional evidence comes from early 
malariotherapy studies where 6 bites led to incubation periods that were slightly 
longer than average, while those from 30+ bites were much shorter (James 1931).  
 The notable consistency of these results suggests a fundamental biological limit, 
and that dosing beyond this threshold potentially involves divergent biological 
pathways. If this inflection point occurs at 5–6 bites, and assuming a median of 15 
and a maximum of 978 sporozoites (Rosenberg 2008), then bites in this range would 
lead to doses of approximately (zero) to 90–5,868 sporozoites. The data from the 
quantitative analysis in this work also suggests that doses above this range of  ~ 1,000 
sporozoites give rise to clinically divergent outcomes (studies XI/XII). Importantly, 
saturation of a biological pathway could also obviate the need for the postulated 
existence of several different types of sporozoites that have been suggested by 
multiple researchers (Shute et al. 1976, Collins et al. 1988). 
3.6 Conclusions 
 Understanding the basis of long-latency in P. vivax malaria infections has 
important implications for the planning of control programs, and both the design and  
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long-term sustainability of surveillance programs in the context of global malaria 
elimination (Mueller et al. 2009, Shanks 2012). Moreover, an improved 
understanding of dose-dependence is crucial for planning human vaccine studies- 
investigators in a recent study were surprised at finding no impact of increasing bite 
challenge on the pre-patent period (Herrera et al. 2009). Our study strongly suggests 
that sporozoite dose is not a main driver of incubation period in naturally or 
experimentally acquired infections, and that the true causes remain to be discerned.  
 The extremely large effect size between the two strains (Chesson and North 
Korean) in this study suggests that parasite strain (and hence genetics) are far more 
important factors in long-latency than sporozoite dose itself. Additionally, the large 
differences by mosquito species in studies XIII–XV suggest important parasite-vector 
interactions; these results bolster the suggestion that Anopheles are far more than just 
simple vectors (Paul et al. 2004). Our results also provide effect estimates that 
reinforce earlier entomological and epidemiological studies suggesting sub-speciation 
within P. vivax by hemispheres (Li et al. 2001, Lover and Coker 2013). 
 Our findings highlight research gaps that should be addressed to ensure that costly 
and technically demanding challenge experiments truly mirror natural infection 
pathways, thereby leading to accurate conclusions about the effectiveness of 
prophylaxis and vaccine candidates. 
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Chapter 4: The distribution of incubation and relapse times in 
experimental infections with the malaria parasite Plasmodium vivax 
 
This work has been published as: Lover AA, Zhao X, Gao Z, Coker RJ, Cook 
AC (2014), The distribution of incubation and relapse times in experimental 
infections with the malaria parasite Plasmodium vivax. BMC Infectious 
Diseases 14, e539. 
 
4.1 Abstract 
 The distributions of incubation and relapse periods are key components of 
infectious disease models for the malaria parasite Plasmodium vivax; however, 
detailed distributions based upon experimental data are lacking. Using a range of 
historical, experimental mosquito-transmitted human infections, Bayesian estimation 
with non-informative priors was used to determine parametric distributions that can 
be readily implemented for the incubation period and time-to-first relapse in P. vivax 
infections, including global subregions by parasite source. These analyses were 
complemented with a pooled analysis of observational human infection data with 
infections that included malaria chemoprophylaxis and long-latencies. The 
epidemiological impact of these distributional assumptions was explored using 
stochastic epidemic simulations at a fixed reproductive number while varying the 
underlying distribution of incubation periods. 
 Using the Deviance Information Criteria to compare parameterizations, 
experimental incubation periods are most closely modelled with a shifted log-logistic 
distribution; a log-logistic mixture is the best fit for incubations in observational 
studies. The mixture Gompertz distribution was the best fit for experimental times-to-
relapse among the tested parameterizations, with some variation by geographic 
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subregions. Simulations suggest underlying distributional assumptions have critically 
important impacts on both the time-scale and total case counts within epidemics. 
 These results suggest that the exponential and gamma distributions commonly 
used for modelling incubation periods and relapse times inadequately capture the 
complexity in the distributions of event times in P. vivax malaria infections. In future 
models, log-logistic and Gompertz distributions should be utilized for general 
incubation periods and relapse times respectively, and region-specific distributions 
should be considered to accurately model and predict the epidemiology of this 
important human pathogen. 
 
4.2 Introduction 
 Malaria caused by Plasmodium vivax has recently entered the global health 
agenda in the context of global malaria elimination. This has followed a re-evaluation 
of the long-held opinion that this parasite causes limited morbidity and essentially no 
mortality; a range of recent studies suggest that it is a major contributor to both in the 
wide-spread regions where it is endemic (Gething et al. 2012, Baird 2013). 
Furthermore, the presence of dormant liver forms (hypnozoites) which can re-activate 
infection is an important barrier in disease control towards global malaria elimination 
(White 2011, Battle et al. 2012). 
 Mathematical and statistical models are an important area of research in malaria 
given the complex dynamics of the parasite-host-vector system (McKenzie 2000, 
Mandal et al. 2011). The majority of malaria models have focused on the species 
common in sub-Saharan Africa, P. falciparum; only recently have efforts been 
directed towards P. vivax (Ishikawa et al. 2003, Pongsumpun and Tang 2007, 
Chamchod and Beier 2013, Roy et al. 2013). The distributions of event times 
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including incubation period have an important role in modelling infectious disease 
(Sartwell 1950), and realistic assumptions about the distributions are crucial for 
accurate models. Published P. vivax models have made a range of implicit and 
explicit assumptions about the functional form of incubation periods and relapse 
intervals with limited empirical justification. Earlier work has focused on statistically 
and clinically significant differences in the epidemiology of sub-populations of this 
parasite (Lover and Coker 2013, Battle et al. 2014), but these epidemiological models 
do not provide well-defined parametric distributions for application within 
mathematical or statistical models.  The purpose of this study is to use data synthesis 
to provide accurate, realistic and readily implementable parameters for modelling P. 
vivax infection event times using several historical human infection datasets.  
 
4.3 Methods 
 We have utilized data from our earlier study of historical human challenge studies 
in two populations: patients receiving pre-antibiotic era neurosyphilis treatments, and 
prison volunteers in experiments for malaria prophylaxis. These two groups of 
institutionalized patients had mosquito-transmitted infections with defined exposure 
dates and complete follow-up (Lover and Coker 2013). The composition of these 
populations can be found in Tables 9 and 10; CONSORT diagrams can be found in 
Figure 7.  
 Individuals without a recorded incubation or relapse (censored observations) have 
not been included in this analysis. ‘Failed’ primary infections were generally not 
reported within the original studies and may represent experimental difficulties. In 
analysis of relapses, our primary consideration was to determine the underlying 
distribution of events for modelling; non-parametric Kaplan-Meier plots of both the 
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full and the censored cohorts (N=320 and N=222), including the proportion with 
relapses, can be found in Appendix B. 
 
Characteristic  Number ( %) 
   
parasite origin New World, Temperate 139 (30.6) 
 New World, Tropical 38 (8.4) 
 Old World, Temperate 57 (12.6) 
 Old World, Tropical 220 (48.5) 
neurological treatment patient No 224 (49.3) 
 Yes 250 (50.7) 
N  454 
 
Table 9. Study population for analysis of time-to-event distributions, incubation period 
(experimental studies). 
 
 
Characteristic  Number (%) 
   
parasite origin New World, Temperate 45 (20.3) 
 New World, Tropical 21 (9.5) 
 Old World, Temperate 130 (58.6) 
 Old World, Tropical 26 (11.7) 
neurological treatment patient No 87 (39.2) 
 Yes 135 (60.8) 
N  222 
 
Table 10. Study population for analysis of time-to-event distributions, relapse period 
(experimental studies). 
 
 
Figure 7. CONSORT diagram, study populations for event time distribution analysis, P. 
vivax malaria.  
Panel A: experimental incubation period study; Panel B: experimental time-to-first relapse 
study. 
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 Data for the infections with long-latency (extended incubation periods) are taken 
from three published studies that involved two unrelated temperate strains; one 
involved drug prophylaxis (Coatney, Cooper, Ruhe, et al. 1950), two were 
observational studies with inferred exposure dates (Brunetti et al. 1954, Kim et al. 
2013), and all include extensive interval censoring in reported event times (Table 11). 
 
Characteristic  Number (%) 
   
malaria chemoprophylaxis No 109 (20.6) 
 Yes 191 (36.1) 
 Unknown 229 (43.3) 
parasite strain Korean 262 (49.5) 
 St. Elizabeth 267 (50.5) 
N  529 
 
Table 11. Study population for analysis of time-to-event distributions in P. vivax 
incubation periods (observational studies). 
 
 Case-patients were exposed to parasites from a range of geographic locations, 
which were characterized by hemisphere and latitude.  As in prior studies and 
historical precedence, the sub-populations from the Western hemisphere are referred 
to as the New World, and Old World region consists of the Eastern hemisphere and 
Pacific regions (Li et al. 2001); and temperate and tropical regions have been split at 
± 27.5° N/S. Many of these data include interval censoring; that is, the event was 
reported as occurring within a specified time interval, but the exact time in unknown 
(Lindsey and Ryan 1998). 
 This study analyses de-identified, secondary data published in the open literature 
(in the public domain); no ethics review was required. Analysis of data from patients 
at the same neurosyphilis treatment centres has been published with an extensive 
discussion of the ethical issues (Weijer 1999); the issues inherent to the prison 
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volunteers in these studies have also received extensive attention (Harkness JM 1996, 
Harcourt 2011, Howes, Battle, et al. 2013). 
 The incubation period refers to the time from parasite exposure to onset of clinical 
symptoms; prepatent periods, which refer to the identification of blood-stage 
parasites, were not included in this analysis. For the experimental studies, all patients 
received only symptomatic treatments; all cases with malaria prophylaxis or radical 
cure were excluded. Relapses were measured from the primary infection as reported 
by the original study authors, and correspond to the onset of new clinical symptoms 
after parasites are no longer visible in the peripheral blood following the primary 
infection (Bruce-Chwatt 1984). These data were examined using survival models, to 
specifically address the non-normal distribution of event times.  
 In this analysis, we examined a range of distributions including exponential, 
gamma, Gompertz, log-logistic, log-normal, Weibull; time-shifted distributions from 
these respective families; and mixture distributions from each distribution family. The 
general forms of these distributions are shown in Figure 8. 
 Model fitting and parameter estimation utilized the Markov-Chain Monte-Carlo 
algorithm (Gelman et al. 2003), and interval censored data were addressed using data 
augmentation methods (Tanner and Wong 1987).  Specifically, the parameter space 
was extended to include both unknown parameters and unknown event times, with 
estimation of the joint distribution of both of them. The marginal distribution for the 
parameters of interest was then obtained by integration over the unknown times. 
Two complementary sets of analyses were performed for each of the experimental 
incubation and relapse datasets. In the first set, the best-fit distribution was found 
using the aggregate data, and then parameters for this optimal distribution were 
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determined for each of the subregions of interest. In the second analysis, the best-fit 
distribution was found for each of the subregions independently. 
 
Figure 8. Comparison of general probability distributions included within time-to-event 
analysis.  
Note:  [shape=0.5, rate=1; shift=0.5 (shifted log-logistic only)]. 
 
 Deviance Information Criterion (DIC) was used for model comparison 
(Spiegelhalter et al. 2002), with standard thresholds to determine strength of 
evidence. That is, an absolute difference between models of < 2 DIC units was taken 
as indicating little difference; from 2-7 units indicating large differences; and > 7 DIC 
units indicating clear evidence of superiority.  
 To examine the sensitivity of the model selection procedure, we multiplied all 
time points by log-normal noise, with mean of 0 on the log scale, plus 0.01 standard 
deviation, i.e. randomly scaled up or down by ± 2%. Model sensitivity was then 
assessed by comparing the DIC from best-fit model with the DIC value from fitting 
the same distributional model to the generated pseudodata. 
 To assess the epidemiological and practical impacts of identified distributions, we  
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performed a series of stochastic compartmental (SIR) models at fixed R0 values while 
varying the underlying distributions. The distributions were implemented using the 
best-fit parameters from our data augmentation process. For these epidemic 
simulations, we utilized the R0 package in R (Obadia et al. 2012) for discrete-time 
models, running 10,000 stochastic simulations, reporting the mean values for each of 
the resulting sets of epidemics. These simulations were run for 200 days, with a 
maximum count of 250 cases per day, with Poisson-distributed new cases. We have 
not incorporated uncertainty in the extrinsic incubation period due to lack of reliable 
data, and we have made the assumption that the incubation period distribution is 
proportional to the generation interval, as P. vivax infections produce infective 
gametocytes rapidly upon onset of clinical symptoms (Bousema and Drakeley 2011).  
 We used non-informative priors for all parameter estimations. Proposal 
distributions were adjusted using estimated means and covariances from pilot runs in 
an iterative process to accelerate convergence; assessment of convergence was 
performed using Geweke’s diagnostic (Geweke 1992). All statistical analyses were 
performed in R (version 2.15.2) (R Core Team 2013), using the packages fitdistrplus, 
flexsurv, grid, MASS, seqinr, FAdist, stats4, R0 and custom-built code for the 
MCMC algorithm. 
 
4.4 Results 
Incubation periods 
 The study of experimental incubation period included 454 case-patients and 
overlaid distributions can be found in Figure 9; DIC comparisons for these 
distributional families for both the aggregate and for subregion-specific incubation 
period data are shown in Table 12. It should be noted for all the results that 
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‘flattening’ of the fitted curves relative to the data-based histograms arises from the 
data augmentation processes. The Deviance Information Criterion (DIC) indicates 
that the shifted log-logistic distribution has a substantially better fit than the second 
best shifted log-normal distribution, as evidenced by a DIC difference of 0.4. Mixture 
distributions of two gammas had limited levels of support (Δ DIC <3) while all other 
distributions were not supported by DIC. The increased complexity of mixture 
distributions does not explain any greater variation in these data, and are also not 
supported by DIC.  
 
 
Figure 9. Comparison of crude (non-data augmented) data and estimated parametric 
models of experimental incubation times, P. vivax malaria.  
Note: (N= 454); Experimental data are in black outlines, and parametric model fits are shown 
with 95% confidence intervals, along with the overall best parametric fit. 
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and in the New World, temperate strains there is very strong evidence for a shifted 
Weibull distribution (Δ DIC = 18.3). Quadrant-specific plots of Kaplan-Meier curves 
with best-fit distributions can be found in Appendix B. 
 
 
Distribution Old World, 
Tropical 
Old World, 
Temperate 
New World, 
Tropical 
New World, 
Temperate 
Global fit, All 
regions 
      
 ∆ DIC ∆ DIC ∆ DIC ∆ DIC ∆ DIC 
exponential 583.1 111.8 109.8 332.9 917.2 
shifted  
exponential 
114.3 45.5 1.8 141.5 275.0 
mixture 
exponential 
- - - - 919.1 
Weibull 76.2 3.7 1.6 0.1 166.4 
shifted 
Weibull 
12.3 2.3 0.2 0.0 33.7 
mixture 
Weibull 
- - - - 40.1 
log-normal 4.7 4.1 1 15.4 16.3 
shifted log-
normal 
2.5 5.5 1.1 17.6 0.4 
mixture log-
normal 
- - - - 18.3 
log-logistic 3.1 0.0 3.4 16.6 14.2 
shifted log-
logistic 
0.0 1.5 2.5 18.3 0.0 
mixture log-
logistic 
- - - - 16.1 
gamma 11 1.3 0.6 9.2 40.3 
shifted 
gamma 
6.5 1.6 1.4 11.1 12.5 
mixture 
gamma 
- - - - 2.7 
Gompertz 159.4 17.3 0.8 10.6 366.0 
shifted  
Gompertz 
42.6 15.5 0.0 4.9 142.1 
mixture 
Gompertz 
- - - - 100.7 
DIC of best-
fit model 
958.8 345.5 163.6 680.1 2374.6 
 
Table 12. Best-fit distributions for experimental incubation times, P. vivax malaria. 
Note: mixture models showed non-normal posteriors and are not reported). Best fitting 
distributions are shown in bold. 
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 The distribution of the 529 cases in confounded and observational studies with 
longer-term incubations is shown in Figure 10 and Table 13; a bimodal peak is clearly 
evident. The studies with the St. Elizabeth strain involved a range of 
chemoprophylaxis regimens, and the Korean strain infections were all observational 
studies that largely included chemoprophylaxis. These results also overwhelmingly 
support a log-logistic distribution; in this case a mixture of two log-logistic 
distributions accurately capture the bimodal distribution commonly observed in 
temperate zone epidemiology. Shifted distributions showed extremely poor fit and are 
not reported. A Kaplan-Meier curve for these data can be found in the Appendix B. 
 
 
Figure 10. Comparison of crude (non-data augmented) data and estimated parametric 
model of observational incubation times, P. vivax malaria. 
Notes: (N=529), Observational data are in black outlines, and parametric model fits are 
shown with 95% confidence intervals, along with the overall best parametric fit. 
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Times to first relapse 
 The results of the time-to-relapse analysis (primary infection to the first relapse) 
are shown in Table 14. We find that mixture distributions provide better fit for the 
total dataset than standard families; specifically, we find the best fit with a Gompertz 
mixture, followed by the log-logistic mixture (Δ DIC = 7.1), log-normal mixture (Δ 
DIC = 6.9) and Weibull mixture (Δ DIC = 7.3). While the differences among these 
three distributions are very minor, all capture the event times poorly relative to the 
Gompertz. The gamma and exponential mixtures both fit poorly (Δ DIC >7). Figure 
11 shows these distributions compared with the experimental data; the district 
bimodal peak is captured by the Gompertz mixture. There is some limited support for 
a shifted Gompertz in the New World Tropical region (Δ DIC = 2.9), but the 
remaining regions, and the global fit to aggregate data, all show strong statistical 
support for a mixture Gompertz distribution. 
 
Standard distributions Mixture distributions 
Base model ∆ DIC Base model ∆ DIC 
exponential 952.4 exponential 551.5 
gamma 570.6 gamma 171.8 
Gompertz 874.2 Gompertz 297.7 
log-logistic 719.3 log-logistic 0.0 
log-normal 688.4 log-normal 41.5 
Weilbull 611.9 Weilbull 193.4 
DIC of best-fit model   2876.7 
 
Table 13. Fitted distributions for observational incubation time studies, P. vivax 
malaria. 
Notes: shifted distributions showed extremely poor fit and are not reported; best fitting 
distribution is shown in bold. 
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Figure 11. Comparison of crude (non-data augmented) data and estimated parametric 
model of first relapse times, P. vivax malaria.  
Notes: (N= 222). Experimental data are in black outlines, and parametric model fits are 
shown with 95% confidence intervals, along with the best overall parametric fit. 
 
Sensitivity analyses 
 A sensitivity analysis was performed for all three datasets and each of the 
subregions individually, and show strong evidence that the models provided good fits 
for the pseudodata by comparisons of the DIC values. Detailed results, estimated 
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the Appendix B. 
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Distribution Old World, 
Tropical 
Old World, 
Temperate 
New World, 
Tropical 
New World, 
Temperate 
Global fit, 
All regions 
 ∆ DIC ∆ DIC ∆ DIC ∆ DIC ∆ DIC 
exponential 112.3 121.8 39.0 106.2 147.4 
shifted  exponential 86.2 80.1 13.3 103.9 134.1 
mixture exponential 109.1 121.1 40.2 106.4 144.9 
Weibull 138.1 221.2 111.8 212.4 190.7 
shifted Weibull 55.6 79.2 13.2 104.5 120.0 
mixture Weibull 80.5 3.8 4.2 14.3 5.4 
log-normal 98.5 111.1 9.0 126.4 178.9 
shifted log-normal 60.4 151.0 34.3 146.6 219.8 
mixture log-normal 75.4 13.6 11.1 17.5 4.7 
log-logistic 93.7 125.2 8.2 121.4 189.3 
shifted log-logistic 60.5 131.9 25.2 129.8 190.1 
mixture log-logistic 94.5 126.8 9.5 122.3 4.1 
gamma 112.0 94.3 9.7 104.7 130.5 
shifted  gamma 54.3 80.8 15.0 105.5 131.0 
mixture gamma 86.4 25.7 9.3 1.1 7.5 
Gompertz 114.0 107.8 2.7 64.1 74.9 
shifted  Gompertz 89.4 79.1 0.0 63.9 73.4 
mixture Gompertz 0.0 0.0 2.9 0.0 0.0 
DIC of best-fit 
model 
144.5 1402.0 219.6 467.17 2596.2 
 
Table 14. Fitted distributions for experimental relapse times, P. vivax malaria. 
Notes: Best fitting distributions are shown in bold. 
 
Epidemic simulations 
 The results of stochastic epidemic simulations can be found in Figure 12. These 
results suggest that at a reproductive number (R0) of 5, the time scale of a modelled 
epidemic varies dramatically based upon the distribution of the incubation period. Use 
of an exponential distribution, as is extremely common in SIR compartmental 
simulations, shows a much more rapid epidemic, with Gompertz and Weibull 
distributions showing more gradual epidemic evolution. Finally, gamma, log-logistic, 
log-normal, and shifted log-logistic have the latest epidemic peaks, and are virtually 
indistinguishable from one another.  
 71 
 
 
Figure 12. Comparison of simulated P. vivax malaria epidemics. 
Note: R0 = 5; mean values from 10,000 simulations for each standard distribution. 
 
 The mean total cases for each set of 10,000 simulations by underlying 
distributions are shown in Table 15. Comparison of these totals shows that within the 
95% confidence intervals, the total number of cases within the epidemic is greater for 
the best-fitting log-logistic and shifted log-logistic distributions relative to 
exponential- and gamma-distributed incubation periods. Simulations with R0= 50 and 
75 produced consistent results but with greater separation of the gamma, log-logistic, 
log-normal, and shifted-log-logistic epidemic curves (results not shown).  
 
Distribution Total case count  (95% CI) 
exponential 1333 (1330 to 1335) 
gamma 2329 (2326 to 2332) 
Gompertz 1950 (1947 to 1953) 
log-logistic 2306 (2304 to 2310) 
log-normal 2328 (2325 to 2331) 
Weilbull 2216 (2214 to 2220) 
shifted log-logistic 2330 (2328 to 2334) 
 
Table 15. Total case counts from epidemic simulations, P. vivax malaria. 
Note:  mean values and 95% CIs from 10,000 simulations for each distribution. 
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4.5 Discussion and conclusions 
 Although some of the earliest simulation models of malaria were directed towards 
P. vivax in epidemics, this parasite has received limited attention from modellers 
(MacDonald et al. 1968). The models that have appeared have used a range of 
distributions for the model parameters of incubation period and time-to-relapse. Some 
of the earliest comprehensive mathematical models for P. vivax did not consider 
distributional assumptions and relied on point estimates (de Zoysa et al. 1991); other 
mathematical models used a log-normal distribution for relapses and a single estimate 
of 15 days for incubation period (Ishikawa et al. 2003), implying an exponential 
distribution. A stochastic model of potential P. vivax transmission within Japan used a 
gamma distribution for the incubation period, an exponential distribution for short 
relapse periods, and a log-normal for longer relapses (Bitoh et al. 2011).   
 Two other comprehensive mathematical models implicitly assume exponential 
distributions for both incubation and times-to-relapse (Águas et al. 2012, Chamchod 
and Beier 2013). A recent comprehensive model including multiple relapse states 
used a 15-day incubation period in simulations to produce a mean relapse interval of 
7.1 months for cases in India, with incubation as an exponential distribution, and 
relapses modelled using a gamma distribution (Roy et al. 2013). 
 Several studies have found that results from infectious disease models can be 
highly sensitive to accurate distributional assumptions (Lloyd 2001, Wearing et al. 
2005); our study reinforces these conclusions in finding the ‘default’ exponential and 
gamma distributions, used for mathematical tractability, inadequately capture the 
complexity of experimental data (Sama et al. 2006, Reich et al. 2009). The results 
from our simulations concur with these statements and suggest that use of best-fitting 
distributions can lead to larger overall case-counts and slower epidemic evolution 
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than would be predicted based upon exponential or gamma distributed incubation 
periods. As the underlying distributional assumptions have large and important 
impacts upon both the time-scale of epidemic evolution and total case counts in P. 
vivax epidemics, these parameters are therefore a critical component of accurate 
models.  
 A range of entomological, molecular, genetic, and epidemiological evidence 
suggests the existence of subspecies within P. vivax (Li et al. 2001, Neafsey et al. 
2012, Lover and Coker 2013); however there has been limited consideration of this 
aspect of parasite biology in published models (Chamchod and Beier 2013). Few 
empirical data exists to support models that include explicit consideration of this 
aspect of the epidemiology; this study provides parameterization for subpopulations 
by climactic zone (temperate and tropical) as well as the postulated subspecies P. 
vivax vivax (E. hemisphere) and P. vivax collinsi (W. hemisphere) to inform region-
based models towards global malaria elimination. Our results show that shifted log-
logistic distributions adequately capture the incubation period for all regions except 
for the New World, temperate parasites, which show strong support for a shifted 
Weibull. However, as these parasite populations were eliminated in the early 20th 
century, they have limited relevance for modern modelling studies (Collins 2013a).  
 The results from the observational long-latent infections have several important 
implications. Although the biological underpinnings of relapse remain obscure 
(Markus 2012), there has been considerable debate that long-latencies may in fact be 
relapses after a sub-clinical primary infection (Horstmann 1973). The results from this 
study show that relapses exhibit quantitatively different behaviour at a population-
level from these long-incubation periods, and this in turn suggests a closer biological 
link to ‘normal’ incubations than to relapses. 
 74 
 Secondly, the congruence of the distributions from experimental and 
observational studies suggests that results from observational studies, while inherently 
limited, may still adequately capture the natural history of infection with P. vivax. 
This finding may greatly expand the utility of available datasets to more completely 
explore the epidemiology of P. vivax. 
 In modelling the time-to-relapse, there is strong support for a mixture Gompertz 
for all event times except in the New World Tropical region, where a shifted 
Gompertz is supported. In addition to simplifying modelling, this concordance of 
distributions in different parasite populations suggests that hypnozoite activation may 
have a common underlying biological trigger, regardless of parasite genetics (Shanks 
and White 2013). While these results for temperate zone parasites are based primarily 
on now-eliminated Russian strains, the parasites currently circulating on the Korean 
peninsula have been reported to have similar relapse patterns (White 2011).   
 However, this study has several limitations. The times we have analysed are from 
adult, non-immune and mostly Caucasian subjects with uncertain inclusion or 
exclusion criteria, and may not represent the experience in high transmission settings 
due to the influence of immunological factors, as well as the poorly understood 
impact of mixed-species malaria infections (Zimmerman et al. 2004). While 
malariotherapy for neurosyphilis treatment has been shown to have minimal impacts 
on incubation periods, larger impacts were found for relapse periods in some sub-
populations of P. vivax (Lover and Coker 2013). 
 A related study examined the length of P. falciparum infections found that the 
total duration of infections were best modelled using a Gompertz distribution (Sama 
et al. 2006). However, the existence of relapses makes defining a duration of infection 
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with P. vivax difficult; multiple lines of evidence suggests that relapses within a 
single infection may be genetically distinct from the primary infection (Collins 2007).  
 Our results suggest that the ‘default’ distributions used in many modelling studies 
(exponential and gamma distributions), may be inadequate to fully capture the natural 
variability and complexity of event times in human infections with Plasmodium vivax 
malaria. Future modelling studies should consider the use of log-logistic and 
Gompertz distributions for incubation periods and relapse times respectively, and the 
region-specific distributions included in this work should be considered to accurately 
model regional variations in the epidemiology of this parasite. Future statistical and 
mathematical models of P. vivax transmission should incorporate the more complex 
distributions identified in this study to maximize the congruence with the true natural 
history and epidemiology of this important human pathogen. 
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Chapter 5: Epidemiological impacts of mixed-strain infections in 
experimental human and murine malaria  
 
5.1 Abstract 
 Infectious diseases within a single host may be composed of multiple strains or 
lineages of a pathogen with differing genetics or antigenicites. These pathogen 
populations may interact with one another, and range of effects have been 
documented that may impact clinical presentation, evolution of virulence, drug-
resistance, and epidemiology of onward transmissions. In most endemic areas, many 
single-species human malaria infections are composed of multiple strains of 
Plasmodium sp., but reports on epidemiological impacts are sparse.  
 In this study we examine a limited set of human experimental infections including 
relapses, with mixed strains of Plasmodium vivax, using survival and binary 
regression to models to examine the population-level impacts of strain interactions 
relative to single strain infections. Using these same modelling frameworks, we then 
examine a wide range of experimental murine malaria infections with mixed-strains 
infections to assess the consistency of these animal models with human infections. 
 We find that while mixed-strain infections do show statistically significant 
differences from single strain infections, we also observe several types of divergent 
behaviour. In parasites that generally target younger red blood cells (reticulocytes), 
mixed-strain infections are significantly different from both single infections, while in 
parasites that infect all red blood cell age-classes, the mixed infection does not differ 
from single-strain infections with the more virulent parasite strains. These results are 
consistent with multiple mathematical models of intra-infection dynamics. We also 
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find remarkable stability in observed differences in P. chabaudi murine infections in 
two laboratories across a decade. 
 These results suggest diverse strategies for virulence management and drug-
resistance containment may be needed to address important differences in the biology 
of different parasite species, and we suggest how alternative analyses could 
potentially maximize results from these technically challenging experiments. 
 
5.2 Introduction 
 Malaria is a major contributor to morbidity and mortality globally, with an 
estimated 207 million cases (95% CI: 135 to 287) and 627,000 deaths (95% CI: 
473,000 to 789,000) in 2012 (World Health Organization 2013a). There are six 
species that generally infect humans, and the interactions between different species 
within a single infection can have important clinical implications (Zimmerman et al. 
2004). Moreover, infections within an individual may be composed of multiple strains 
(clonal populations) of a single species, which may interact both with one another and 
with the host immune system.  
 The implications of these interactive populations have been explored through 
multiple lines of research, using two types of models: mathematical/statistical models, 
and experimental animal systems. A range of effects have been proposed or measured 
from these efforts; recent reviews have focused on both clinical (Balmer and Tanner 
2011) and general ecological (Alizon et al. 2009) considerations. Briefly, the 
interaction between parasite populations may lead to parasite competition or to 
parasite mutualism; to the evolution of virulence and drug susceptibility; and may 
facilitate genetic exchange within infections (Balmer and Tanner 2011).  
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 In a range of epidemiological settings, the majority of individual P. vivax and P. 
falciparum infections are composed of multiple strains. Recent pyrosequencing has 
demonstrated highly diverse suites of parasites within an infection (Juliano et al. 
2010), but other studies have suggested that mixed-clone P. falciparum infections are 
generally very closely related, and only rarely consist of highly divergent parasites 
(Nkhoma et al. 2012).  
 Longitudinal studies from Papua New Guinea examining both P. falciparum and 
P. vivax populations suggest a cycling of different clonal suites, which are rapidly 
displaced by newer, less-related strains (Bruce et al. 2000, Mackinnon and Read 
2004). Studies on population-level diversity suggests that parasite factors could be the 
single largest component of observed clinical differences in severity or virulence 
(Mackinnon et al. 2000); moreover, these infections may represent an underutilized 
tool to explore complex transmission dynamics (Bordes and Morand 2009, de Araujo 
et al. 2012).  
 However, the epidemiological (population-level) impacts of mixed-strain 
infections have received more limited attention due to difficulties in data capture and 
inherent ethical considerations in studies involving human subjects. In this study, we 
re-examine historical human experimental infections with P. vivax using modern 
analytical techniques, and then compare these results with re-analyses of data from 
murine model systems, to assess the consistency between these inherently limited 
human data and the much larger corpus of animal models and ecological theory.  
  
Strain theory and virulence 
 The concept of microbial strains is pervasive throughout the medical and malaria 
literature, however, no consensus exists on what these clinical isolates truly represent 
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(Balmer and Tanner 2011, McKenzie et al. 2008); in general they refer to clonal, or at 
least closely-related, populations. A wide range of observations have been made 
regarding the clinical impact of strains, and include reports of differences in 
virulence, clinical severity, transmissibility, and both the number and spacing of 
hypnozoite-derived relapses in P. vivax infections (McKenzie et al. 2008). Recent 
molecular and genetic methods have also added to this knowledge base by 
characterizing both inter- and intra-host infections; these studies suggest that while 
many strains/isolates represent a diversity of clonal populations, they generally 
produce stable clinical/immunological responses (McKenzie et al. 2008).  
 Previous analyses in murine systems have almost entirely focused on pooled 
haematological or parasitological outcomes as proxies for virulence (comparing 
means or geometric means from all surviving animals), but full multivariate analyses 
of outcomes or consideration of times-to-events have received very limited attention.  
While time itself is a critical component of virulence, analyses have generally focused 
on analysis at several (potentially arbitrary) time points. Finally, in many cases, 
censoring of subjects has not been considered- that is, animals are removed from 
analysis; beyond a potential for introducing biases, this greatly reduces the power of 
the analysis (Rothman et al. 2008). Finally, many studies have used simple p-values 
to evaluate significance, as is the norm in ecology; however, these do not allow 
consideration of the effect size (statistically significant effects may not be clinically/ 
biologically important). A fuller consideration of virulence, and of effect size 
measures may provide important additional information beyond these summary 
statistics. 
 Lastly, the concept of ‘virulence’ is complex and encompasses the outcomes of 
many different and interrelated interactions between the parasites and host. While a 
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range of definitions have appeared (Poulin and Combes 1999, Casadevall and Pirofski 
2001), herein we consider it as ‘parasites populations that maximally exploit host 
resources’ to capture the range of endpoints examined in this study, with a focus on 
direct parasite-induced mortality. 
 
5.3 Methods 
Data sources 
 The human study data included in this analysis was obtained during a series of 
rigorous human challenge experiments among prison volunteers in the 1940’s - 50’s 
in a program to develop novel antimalarial drugs; all case-patients were malaria-naïve 
white males. Infections were via mosquito challenge, there was complete follow-up, 
and patients were protected from super-infection due to the institutional nature of 
these populations. Analysis of incubation periods includes 44 patients inoculated with 
the St. Elizabeth strain; 131 with Chesson parasites; and nine patients with mixed 
infection. Analysis of relapses includes 38 patients with St. Elizabeth; 19 with 
Chesson, and nine patients with mixed infection (Table 16).  
 Full details for human challenge infections including literature search criteria and 
primary literature references can be found in (Lover and Coker 2013); data for the 
mixed strain challenge are from (Cooper et al. 1950). All of these infections were 
transmitted by infected vectors (generally Anopheles quadrimaculatus). Relapse times 
are presented as time from mosquito inoculation. All single-strain infections had 
symptomatic-only treatment with quinine; however, all mixed-strain inoculations had 
chloroquine exposure after the primary attack. The Chesson strain of P. vivax has 
been described as being extremely virulent, with rapid onset of symptoms and with a 
propensity for many closely spaced relapses (Ungureanu et al. 1976); the St. 
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Elizabeth is a milder ‘temperate’ strain first isolated in the southern US (Collins 
2013a). 
End point Treatment n % of total 
Incubation period Mixed 9 4.9 
 Chesson 131 71.2 
 St. Elizabeth 44 23.9 
 Total 184 100.0 
    
Time-to-first relapse Mixed 9 13.6 
 Chesson 19 28.8 
 St. Elizabeth 38 57.6 
 Total 66 100.0 
 
Table 16. Study population, historical human challenge experiments with P. vivax. 
 
 Data for the P. yoelii infections (Table 17) were extracted from (Hargreaves et al. 
1975); although the authors refer to these parasites as P. berghei yoelii, a later 
revision elevated these parasites to the species-level as P. yoelii (Killick-Kendrick 
1974, Perkins et al. 2007). CF1 mice were inoculated with 106 parasitized RBCs, and 
2 x 106 in the mixed infections. The mild strain of ‘17X’ was obtained from a wild 
thicket rat; the virulent form was obtained after serial passages in rodents and An. 
stephensi (Hargreaves et al. 1975). 
 
Treatment n % of total 
Mixed 6 33.3 
‘17X mild’ 6  33.3 
‘17X virulent’ 6 33.3 
Total 18 100.0 
 
Table 17. Study population, murine challenge experiments with P. yoelii. 
 
 Data for the first set of P. chabaudi murine challenge experiments (Table 18) 
were taken from (Snounou et al. 1992). Male CBA/ca mice were inoculated with 104 
parasitized erythrocytes; mixed infections were inoculated with 1 x 104 of each strain.  
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Treatment n % of total Mortality % (95% CI) 
AS 10 10 20 (2.5 – 55.6) 
CB 10  10 80 (44.4 – 97.5) 
DS 10 10 60 (26.2 – 87.8) 
AS + CB 10 10 100 (69.2 – 100) 
CB + DS 10 10 100 (69.2 – 100) 
AS + CB 10 10 40 (12.2 – 73.8) 
Total 60 100.0 - 
 
Table 18. Study population, murine challenge experiments with P. chabaudi (set I). 
Source: (Snounou et al. 1992) 
 
 
 Data for the later murine challenges with P. chabaudi (Table 19) are from the 
work of Bell et al. and are available from the Drydad data repository (Bell et al. 2006, 
2014). In these infections, C57B1/6J inbred female mice were inoculated with 106 
parasites; mixed infections received a total dose of 2 x106, however the authors cite 
prior studies suggesting this 2-fold difference has minimal impact on outcomes (Bell 
et al. 2006). The strains utilized are from diverse sources and were chosen specifically 
to mimic the diversity within wild parasite populations. Prior work suggested that the 
AJ and AT strains were more virulent relative to AS and CB; however, in the first 
experiment, CB was unexpectedly virulent and was replaced by CW for the second 
replicate. This analysis was focused on the initial acute phase of infections before 
specific immunological responses occur; therefore surviving mice were censored one 
day past the last recorded fatality (on day 15). 
 
Methods 
 Where data allowed, preliminary analyses of the relationship between parasite 
strains and times-to-event used non-parametric analyses (Kaplan-Meier curves and 
related methods) to determine if statistically significant differences exist; differences 
were compared using the Peto-Peto test due to differences in censoring and non-
proportional hazards (Klein and Kleinbaum 2005, Lachin 2011). These analyses were 
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then followed by multivariate analysis (survival and/or log-binomial models for time-
to-event or mortality) to estimate the magnitude of observed effects.  
 
Treatment n % of total Mortality % (95% CI) 
1. AS 10 10 0 (0 – 30.8) 
2. AJ 10 10 70 (34.8 – 93.3) 
3. AT 10 10 30 (6.7 – 65.2) 
4. CB 5 5 60 (14.7 – 94.7) 
5. AS+AJ 10 10 30 (6.7 – 65.2) 
6. AS+AT 10 10 50 (18.7 – 81.3) 
7. AS+CB 5 5 40 (5.3 – 85.3) 
8. AJ+AT 10 10 50 (18.7 – 81.3) 
9. AJ+CB 5 5 100 (47.8 – 100) 
10. AT+CB 5 5 80 (28.4 – 99.5) 
11. CW 5 5 0 (0 – 52.2) 
12. AS+CW 5 5 20 (0.51 – 71.6) 
13. AJ+CW 5 5 20 (0.51 – 71.6) 
14. AT+CW 5 5 40 (5.3 – 85.3) 
Total 100 100.0 - 
 
Table 19. Study population, murine challenge experiments with P. chabaudi (set II). 
Note: Source (Bell et al. 2006). 
 
 
 A diverse range of parametric and semi-parametric survival models was explored 
in the analysis of these human and murine experimental data. However, extensive 
issues were observed with lack-of-fit, non-convergence due to collinear strains, 
crossing survival curves, or complete separation. Moreover, standard survival models 
are not applicable in the presence of crossing survival curves, as a single hazard ratio 
is an inadequate measure of a time-dependent risk of event. 
 Due to these analytical issues, a set of complementary analyses was performed so 
that all studies were analysed within a consistent analytical framework. First, 
pseudovalues were computed and used to compare differences in restricted mean 
survival times (Parner and Andersen 2010, Andersen and Perme 2010). This approach 
has been specifically suggested to assess differences in survival when hazard ratios 
may be an inaccurate measure of differences; the restricted mean survival times  
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(RMST) were calculated at just before the end of follow-up time (symbolized as t*) 
(Royston and Parmar 2011). Secondly, the incidence rate ratios (that is, the ratio of 
total number of events per follow-up time, per strain) were compared using Poisson 
models.  
 Finally, where possible, full multivariate methods were used to assess the 
magnitude of strain differences, using the optimal models for each dataset. For the 
study of P. yoelii mortality, flexible parametric survival models were used to 
comprehensively model the underlying hazard function and to provide estimates of 
effect size with adjustment for covariates. These models are comprehensive 
alternatives to standard Cox survival models which allow greater flexibility in model-
fitting and prediction (Royston and Parmar 2002, Royston and Lambert 2011).  
 For the first study of P. chabaudi mortality (Snounou et al. 1992), regressions for 
a binomial outcome (mortality) were used to quantify the differences in mortality 
between strains. As the outcome of mortality was common within this study, the odds 
ratios provided by standard logistic regression models would be biased estimates of 
risk; we therefore used alternative models for binary outcomes. Two models have 
been widely used: log-binomial and robust Poisson models; importantly, these 
provide risk ratios as opposed to the odds ratios produced in logistic regression. Both 
options provided consistent effect size estimates for these data; however, we report 
the Poisson models as they have been reported to be more robust to outliers and 
displayed fewer issues with model convergence (Zou 2004, Chen et al. 2014). 
 For the second study of P. chabaudi mortality (Bell et al. 2006), regressions for a 
mortality outcome were also used to quantify the differences in mortality between 
strains. Both model parameterizations in this case had convergence issues, so the 
‘COPY’ method of Petersen and Deddens was used to facilitate model convergence 
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and estimation of risk ratios (Petersen and Deddens 2006). This method consists of 
doubling the dataset, reversing the outcomes in all added cases, and then weighting 
the reversed outcomes at 0.001:0.999 relative to the original data (Cummings 2009).  
 For all models in this analysis model parsimony was assessed using Akaike and 
Bayesian information criteria (AIC/BIC); residuals and standard goodness-of-fit tests 
were used to assess adequacy of the robust Poisson and restricted mean survival 
models; the fit of the flexible parametric survival model was judged using overlaid 
comparisons with the non-parametric Kaplan-Meier curves. ‘Robust’ (Huber-White) 
error structure was used in all models to address the non-independence of subjects 
within study arms (Williams 2000). Models were assessed for proportional hazard 
violations using Schoenfeld residuals; however the models reported all have no 
proportional-hazard assumption. 
 All analyses were performed using Stata 13.1 (College Station, TX, USA) and all 
tests were two-tailed, with α = 0.05. 
 
5.4 Results 
Plasmodium vivax infections- incubations 
 The results from Kaplan-Meier analysis of incubation periods (time from 
mosquito exposure to febrile illness) are shown in Figure 13 and Table 20. Infections 
with the Chesson strain had the shortest incubation periods, with intermediate (and 
crossing) curves from mixed infections, followed by the St. Elizabeth strain 
infections. The arithmetic median incubation periods were: Chesson 12 days (95% CI: 
12 to 12), mixed infection 14 (12 to 14), and St. Elizabeth 15 (95% CI: 15 to 16), and 
the differences in restricted mean survival time (RMST) are all significant (mixed 
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infection vs. St. Elizabeth; and Chesson vs. St. Elizabeth, both p < 0.001; Chesson vs. 
mixed, p = 0.001). 
 
Figure 13. Kaplan-Meier curves comparing incubation periods in single strain and 
mixed-strain infections in human challenge experiments with P. vivax. 
Note: N= 184 
 
Parasite strain Incidence rate ratio,  
(95% CI) 
p-value, IRR 
 
RMST 
difference, (SE) 
p-value, RMST 
St. Elizabeth vs. Chesson (ref) 0.80 (0.77 – 0.83) < 0.001 3.1 (0.25) 0.001 
Chesson vs. mixed (ref) 1.1 (1.03 – 1.15) < 0.001 -1.1 (0.34) 0.001 
St. Elizabeth vs. mixed (ref) 0.87 (0.82– 0.91) < 0.001 2.0 (0.37) < 0.001 
 
Table 20. Comparison of incubation periods in human challenge experiments with 
mixed-strain infections of P. vivax. 
Notes: (N= 184) (RMST at t* = 18 days); entries in bold are significant with p < 0.05. 
 
 Comparisons between incidence rate ratios are consistent with the Kaplan-Meier 
analysis: infections with the St. Elizabeth strain had an IRR of 0.80 (95% CI: 0.77 – 
0.83; p < 0.001) relative to the more virulent Chesson strain. Relative to mixed 
inoculations, Chesson infections had an IRR of 1.1 (1.03 – 1.15; p < 0.001), with St. 
Elizabeth having an IRR of = 0.87 (0.82 – 0.91; p < 0.001). That is, over the follow 
up period, case-patients infected with Chesson parasites had a ~10% faster rate, and 
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those infected with St. Elizabeth parasites a ~13% slower rate, of presenting with 
febrile illness respectively, than case-patients infected with mixed-strain parasites. 
Plasmodium vivax infections- relapses 
 Kaplan-Meier plots for time-to-first relapse (measured as the time from primary 
infection) are shown in Figure 14. Rapid times to relapse are apparent in infections 
with the Chesson strain, followed by an intermediate curve from mixed inoculations, 
with St. Elizabeth relapses having the slowest times-to-relapse, spaced out over ~10 
months. The median uncensored relapse times are: Chesson 6.3 weeks (95% CI: 5.6 
to 7.1); mixed 11.4 weeks (9.2 to 38.5); and St. Elizabeth 41.7 weeks (39.5 to 43.0). 
 
 
Figure 14. Comparison of Kaplan-Meier curves, time-to-first relapse, human challenge 
infections with mixed-strain P. vivax. 
Note: N= 66. 
 Comparison of the incidence rates for relapses (Table 21) suggests that relative to 
the Chesson strain, infections with the St. Elizabeth strain have an incidence rate ratio 
of 0.23 (95% CI: 0.13 – 0.41, p < 0.001). In comparison to mixed strain infections, 
infections with the St. Elizabeth strain had an IRR of 0.44 (0.27 – 0.70, p = 0.001),  
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while the Chesson infections do not achieve significance, with an IRR of 1.9 (0.92 – 
3.9; p = 0.081). That is, in single strain infections with St. Elizabeth parasites, there is 
~ 2.3 fold, and ~4.3 fold, slower rate of relapse relative to mixed infections and to 
Chesson strain infections respectively, while mixed infections do not show a 
significant difference from infections with Chesson parasites. 
 
Parasite strain Incidence rate ratio,  
(95% CI) 
p-value,  
IRR  
 
RMST  
difference (SE) 
p-value,  
RMST 
St. Elizabeth vs. Chesson (ref) 0.23 (0.13 – 0.41) < 0.001 28.1 (2.8) < 0.001 
Chesson vs. mixed (ref) 1.9 (0.92 – 3.9) 0.081 - 8.8 (4.4) 0.042 
St. Elizabeth vs. mixed (ref) 0.44 (0.27 – 0.70) 0.001 19.2 (4.3) < 0.001 
 
Table 21. Comparison of time-to-first relapse (from parasite inoculation) in human 
challenge experiments with P. vivax. 
Notes: (N= 66) (RMST at t* = 45 weeks); entries in bold are significant with p < 0.05. 
 
 Comparison of the RMSTs at t*=45 weeks are significant for both St. Elizabeth 
vs. Chesson (p < 0.001) and vs. mixed infection (p < 0.001); and the Chesson 
infections show only a marginally significant difference from mixed strain infections 
(p = 0.042). 
 
Plasmodium yoelii infections 
 The results from survival analysis of mortality outcomes in experimental murine 
P. yoelii infections are shown in Figure 15 and Table 22. There are clearly disenable 
and statistically significant differences in the time-to-mortality between both of the 
single strains and mixed infections, and between the two single-strain infections. In 
Kaplan-Meier analysis, the Peto-Peto log-rank test indicates significant differences 
between the strains (‘17X-mild’ vs. ‘17X-virulent’, p= 0.0010; ‘17X-virulent’ vs. 
mixed, p = 0.0103; ‘17X-mild’ vs. mixed, p = 0.0034); comparison of the RMST  
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differences (Table 22) at t*= 22 days shows comparable p-values (‘17X-mild’ vs. 
‘17X-virulent’, p < 0.001; ‘17X-virulent’ vs. mixed, p = 0.002; ‘17X-mild’ vs. mixed, 
p = < 0.001). In flexible parametric survival models, with mixed infection as the  
reference, the ‘17X- virulent’ strain showed an hazard ratio (HR) of 7.5 (95% CI: 1.5 
to 38.0; p = 0.015); the ‘17X - mild’ strain had an HR of 0.049 (95% CI: 0.011 to 
0.21; p < 0.001). These imply that relative to mixed strain infections, mild strain 
infections have ~7.5 times lower risk, and virulent strain infections have ~20 times 
greater risk, of mortality in P. yoelii infections. The incidence rate ratios are also 
consistent with these other analyses, and suggest approximately 2-fold faster (vs. 
virulent) and 2-fold slower (vs. mild strain) mortality rates in mixed-strain infections. 
 
 
Figure 15. Kaplan-Meier and flexible-parametric survival model curves comparing 
time-to-mortality in mixed-strain infections in murine challenge experiments with P. 
yoelii.  
Note: (N= 18). 
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Parasite strain p value, 
Peto-
Peto test 
RMST  
difference 
(SE) 
p-value, 
RMST 
IRR  
(95% CI) 
P 
values, 
IRR 
Hazard ratio, 
95% CI 
p value, 
 hazard 
ratio 
‘17X- mild’ vs. 
‘17X- virulent’ (ref) 
0.0010 14.9 (1.3) < 0.001 0.51 
(0.36 – 0.72) 
< 0.001 0.0065  
(0.00091- 
0.046) 
< 0.001 
‘17X- virulent’ vs. 
mixed  (ref) 
0.0103 - 4.8 (1.6) 0.002 1.96 
(1.39 – 2.76) 
< 0.001 7.51  
(1.49 – 37.87) 
0.015 
‘17X- mild’ vs. 
mixed (ref) 
0.0034 10.0 (1.9) < 0.001 0.23 
(0.075 – 0.14) 
0. 004 0.049  
(0.011 - 0.21) 
< 0.001 
 
Table 22. Comparison of time-to-mortality in murine challenge experiments with P. 
yoelii. 
Notes: (N=18) (RMST at t* = 22 days); IRR= incidence rate ratio; entries in bold are 
significant with p < 0.05. 
 
Plasmodium chabaudi infections  
 The analysis of P. chabaudi data from Snounou et al. is shown in Table 23, with 
mortality as an endpoint. Overall, mixed-strain infections showed a significant 
difference in risk of mortality relative to single infections: any mixed infections vs. all 
single, (RR = 1.6; 95% CI: 1.1 to 2.3, p = 0.009). While mortality was analysed 
within a unified model for all infections, results are presented with differing reference 
categories within each triad (two single infections and the corresponding mixed 
infection). Shown first within each triad is the ‘control’ scenario- that is, a direct 
comparison between the two single strain infections, followed by comparisons of each 
single-strain infection to the mixed-strain scenario. In these data, only a single triad 
shows significant differences between the two ‘pure’ infections; a significant 
difference exists between single infections with AS (avirulent) and CB (virulent) 
strains; and the mixed infection remains significantly different from single-strain AS 
infections (RR = 0.20; 95% CI 0.58 to 0.70, p = 0.012). However, no evidence for 
difference was found in comparison with single CB infections (RR = 0.8; 0.59 to 1.1, 
p = 0.162). 
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Parasite strain triad 
(more virulent strains in  
bold) 
Comparison Risk ratio  
(95% CI) 
p-value, risk ratio  
 
i. Mixed AS/CB (ref) AS vs. CB (ref) 0.25 (0.069 – 0.91) 0.035 
 AS vs. AS+CB (ref) 0.20 (0.58 – 0.70) 0.012 
 CB vs. AS+CB (ref) 0.80 (0.59 – 1.1) 0.162 
ii. Mixed DS/CB (ref) DS vs. CB (ref) 0.75 (0.41 – 1.4) 0.346 
 DS vs. DS+CB (ref) 0.60 (0.36 – 0.99) 0.050 
 CB vs. DS+CB (ref) 0.80 (0.59 – 1.1) 0.162 
iii. Mixed AS/DS (ref) AS vs. DS (ref) 0.33 (0.09 – 1.3) 0.111 
 AS vs. AS+DS  (ref) 0.33 (0.09 – 1.3) 0.111 
 DS vs. AS+DS (ref) 1.0 (0.49 – 2.1) 1.0 
 
Table 23. Log-binomial models for mortality in mixed infections, murine challenge 
experiments (set I) with P. chabaudi. 
Notes: (N= 60); entries in bold are significant with p < 0.05. 
 
 Within the second set of P. chabaudi infections, visual comparison of the Kaplan-
Meier curves suggests highly complex behaviour between strains (Figure 16), as 
shown by the crossing of the survival curves in many of the infection triads. As 
standard log-rank tests are not applicable when survival curves cross, we have utilized 
the comparison of restricted mean survival times.  
 Overall, mixed infections showed no significant difference in time-to-mortality 
from single infections: any mixed infection vs. all single-strain infections (Peto-Peto 
test, p = 0.2141; RMST difference = -0.5(SE 0.5), p = 0.356); or in risk of mortality 
relative to single infections (RR = 1.4; 95% CI: 0.86 to 2.4, p = 0.168). 
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Figure 16. Kaplan-Meier curves comparing time-to-mortality in single strain and mixed-
strain infections in murine challenge experiments with P. chabaudi. 
Note: N= 100. 
 
 Differences in mortality between strains of P. chabaudi are shown in Tables 24 
and 25. As above, we present each infections triad with different reference groups. 
Several broad trends are apparent in these results.  Specifically, in multivariate binary 
outcome models, mixed infections are indistinguishable from single infections with a 
more virulent strain, and are significantly different from single infections with less 
virulent strains. For example, in triad i. (Table 24), a significant difference exists 
between single infections with AS (avirulent) and AJ (virulent) strains; and the mixed 
infection remains significantly different from AS infections (RR = 0.0033; 95% CI 
0.000092 to 0.012, p = < 0.001). However, no evidence for a significant difference 
was found when compared with single-strain AJ infections (RR = 2.3; 95% CI: 0.084 
to 6.5, p = 0.105).  
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 While the RMST differences are consistent with these risk ratios, the Peto-Peto 
log-rank test shows similar trends but does not reach significance (p = 0.068). In 
summary, we find that mixed-strain infections are indistinguishable from the single-
strain infections with that more virulent strain, but are significantly different from 
single-strain infections with the less virulent strain, in cases where there are 
significant differences between the two single-strain infections. It should be noted that 
the extremely small reported RRs are due to zero events in some strain categories. 
 
Parasite strain triad 
(more virulent strains in  
bold) 
Comparison p-value, 
Peto-Peto test 
RMST  
difference 
(SE) 
p-value   
RMST 
difference  
 
Risk ratio  
(95% CI) 
p-value, 
risk 
ratio  
 
i. Mixed AS/AJ AS vs. AJ (ref) 0.0015 3.4 (0.84) < 0.001 0.0015 
(0.00054 – 
0.0038) 
< 0.001 
 AS vs. AS+AJ (ref) 0.0679 1.4 (0.71) 0.049 0.0033 
(0.00092 – 
0.012) 
< 0.001 
 AJ vs. AS+AJ (ref) 0.0792 -2.0 (1.1) 0.070 2.32  
(0.84 – 6.5) 
0.105 
ii. Mixed AS/AT AS vs. AT (ref) 0.0685 1.9 (0.93) 0.041 0.0033 
(0.00091 – 
0.012) 
< 0.001 
 AS vs. AS+AT (ref) 0.0130 1.6 (0.89) 0.072 0.0020 
(0.00068 – 
0.0059) 
< 0.001 
 AT vs. AS+AT (ref) 0.5584 - 0.30 (1.3) 0.816 0.61  
(0.19 – 1.88) 
0.381 
iii. Mixed AS/CB AS vs. CB (ref) 0.0062 3.0 (1.2) 0.012 0.0018 
(0.00054 – 
0.0056) 
< 0.001 
 AS vs. AS+CB  (ref) 0.0350 1.4 (0.94) 0.145 0.0026 
(0.00063 – 
0.011) 
< 0.001 
 CB vs. AS+CB (ref) 0.3547 - 1.6 (1.4) 0.266 1.50  
(0.41 – 5.5) 
0.539 
iv. Mixed AJ/AT AJ vs. AT  (ref) 0.1933 - 1.5 (1.3) 0.232 2.32  
(0.83 – 6.55) 
0.109 
 AJ vs. AJ+AT (ref) 0.4769 - 0.90 (1.2) 0.463 1.40  
(0.67 – 2.9) 
0.371 
 AT vs. AJ+AT (ref) 0.5080 0.60 (1.3) 0.641 0.61  
(0.19 – 1.9) 
0.379 
v. Mixed AJ/CB AJ vs. CB (ref) n/a - 0.43 (1.4) 0.762 1.2  
(0.52 – 2.86) 
0.652 
 AJ vs. AJ+CB (ref) 0.2534 1.6 (1.3)  0.222 0.74  
(0.45 – 1.2) 
0.184 
 CB vs. AJ+CB (ref) 0.1293 2.0 (1.5) 0.176 0.60  
(0.30 – 1.2) 
0.163 
 
Table 24. Comparison of Kaplan-Meier estimator, restricted mean survival times, and 
risk ratios from binomial models for mortality in mixed infection in murine challenge 
experiments (set II) with P. chabaudi. 
Notes: (RMST at t* = 15 days); entries in bold are significant with p < 0.05); ‘na’ signifies 
test is not applicable due to crossing survival curves. 
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 The sole outlier to these trends occurs in triad vii. (Table 25), which compares two 
avirulent strains: AS and CW. While there is no evidence for a difference between the 
two single-strain infections, the comparisons of the mixed infections are significant in 
the binomial response models. Both of the single strain infections had no mortality, 
while 20% of the mice infected with mixed-strain parasites died.  
 
Parasite strain triad 
(more virulent strains in  
bold) 
Comparison p value, 
Peto-Peto test 
RMST  
Difference 
(SE) 
p-value   
RMST 
difference  
 
Risk ratio  
(95% CI) 
p-value, 
risk 
ratio  
 
vi. Mixed AT/CB AT vs. CB (ref) n/a 1.1 (1.5) 0.470 0.52  
(0.16 – 1.7) 
0.290 
 AT vs. AT+CB (ref) 0.1245 2.5 (1.5) 0.099 0.39  
(0.14 – 1.1) 
0.084 
 CB vs. AT+CB (ref) 0.3602 1.4 (1.6) 0.388 0.75  
(0.32 – 1.7) 
0.503 
vii. Mixed AS/CW AS vs. CW (ref) 0.1573 0.33 (0.32) 0.917 0.06  
(0.20 – 4.5) 
0.955 
 AS vs. AS+CW (ref) 0.1573 1.0 (0.95) 0.279 0.0048 
(0.00066 – 
0.035) 
< 0.001 
 CW vs. AS+CW (ref) 0.3173 1.0 (0.90) 0.266 0.0050 
(0.00058 – 
0.043) 
< 0.001 
viii. Mixed CW/AJ CW vs. AJ (ref) 0.0230 3.4 (0.93) < 0.001 0.0015 
(0.00039 – 
0.0057) 
< 0.001 
 CW vs. CW+AJ (ref) 0.3173 1.4 (1.3) 0.266 0.0050 
(0.00058- 
0.042) 
< 0.001 
 AJ vs. CW+AJ (ref) na -2.0 (1.6) 0.209 3.3 (0.54 – 
20.7) 
0.196 
ix. Mixed CW/AT CW vs. AT (ref) 0.1952 1.9 (1.1) 0.067 0.0035 
(0.00070 – 
0.017) 
< 0.001 
 CW vs. CW+AT (ref) 0.1360 2.2 (1.2) 0.071 0.0050 
(0.00058 – 
0.043) 
< 0.001 
 AT vs. CW+AT (ref) na 0.33 (1.6) 0.084 1.4 
(0.19 – 10.9) 
0.729 
 
Table 25. Comparison of Kaplan-Meier estimator, restricted mean survival times, and 
risk ratios from binomial models for mortality in mixed infection in murine challenge 
experiments (set II) with P. chabaudi (continued). 
Notes: (RMST at t* = 15 days); entries in bold are significant with p < 0.05); ‘na’ signifies 
test is not applicable due to crossing survival curves. 
 
 Finally, to complement these two separate analyses of P. chabaudi infections, two 
further comparisons were made. All P. chabaudi infections from both studies were 
compared (N= 160) to assess the potential range in parasite virulence, and the overall  
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impact of mixed-strain parasitemia (Table 26). A limited increase in the risk of 
mortality from any mixed-strain infections relative to any having any single-strain 
infection was observed (RR = 1.44; 95% CI 1.04 to 2.01, p = 0.026); as such, any 
infection with mixed parasite populations had a 44% greater risk of mortality relative 
to any single-strain infection, across a range of parasite clones with varying virulence.  
 
Parasite  
strain 
Risk ratio 95% CI,  
risk ratio  
p-value, 
risk ratio  
CW  4.5 e-6 9.9 e-7 – 0.000020 < 0.001 
AS ref. ref. ref. 
AS + CW 3.51 0.41 – 30.32 0.253 
AJ + CW 3.51 0.41 – 30.32 0.253 
DS 4.40 1.04 – 18.64 0.044 
AT 4.70 0.99 – 22.26 0.051 
AS + DS 4.94 1.21 – 20.13 0.026 
AJ + AS 5.27 1.10 – 25.25 0.038 
CB 6.54 1.70 – 25.10 0.006 
AT + CW 7.03 1.35 – 36.48 0.020 
AS + CB 8.00 2.22 – 28.81 0.001 
CB + DS 8.22 2.22 – 30.51 0.002 
AS + AT 8.78 2.18 – 35.35 0.002 
AJ + AT 8.78 2.18 - 35.35 0.002 
AJ 10.97 3.00 – 40.12 < 0.001 
AT + CB 14.06 3.75 – 52.67 < 0.001 
AJ + CB 17.57 5.06 – 61.06 < 0.001 
 
Table 26. Comparison of risk ratios for mortality by strains in murine challenge 
experiments with P. chabaudi, using robust Poisson regression. 
Notes: (N= 160), models adjusted for parasite dose and experiment number; entries in bold 
are significant with p < 0.05. 
 
 Secondly, a comparison of pooled data of the AS/CB triad from the two different 
sets of studies is presented in Table 27. This parasite pairing appears in both sets of 
experiments; as expected, parasite dose was not significant in these models. Within 
this triad, the risk of mortality in mixed infections was significantly greater relative to 
having either single-strain infection: RR = 2.5; 95% CI 1.6 to 3.6, p < 0.001. The  
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difference between the single strain AS and CB infections remained highly significant  
AS vs. CB (ref) (RR = 0.13; 95% CI: 0.034 to 0.51, p= 0.003), as did the AS vs. 
mixed (ref) (RR= 0.10; 95% CI: 0.027 to 0.38, p= 0.001); while infection with CB 
parasites vs. mixed infection showed only a marginally significant difference (RR = 
0.76; 95% CI: 0.59 to 0.998, p =0.048). 
 
Parasite strain triad 
(virulent strains in  
bold) 
Comparison Risk ratio  
(95% CI) 
p-value, risk ratio  
 
Mixed AS/CB  AS vs. CB (ref) 0.13 (0.034 – 0.51) 0.003 
 AS vs. AS+CB (ref) 0.10 (0.027 – 0.38) 0.001 
 CB vs. AS+CB (ref) 0.76 (0.59 – 0.998) 0.048 
 
Table 27. Comparison of risk ratios from binomial models for mortality in mixed 
infection with AS and CB strains in murine challenge experiments (sets I and II) with P. 
chabaudi. 
Notes:  (N= 57); entries in bold are significant with p < 0.05. 
 
5.5 Discussion 
Human experimental studies 
 Early published studies include a small set of co-inoculations done in Florida, 
which were then propagated via mosquitoes (Boyd et al. 1938, 1941). These studies 
appeared to show that co-inoculation led to a delay in parasite clearance, and impaired 
acquisition of immunity to either strain as assessed by subsequent re-infections; 
however, no measures of virulence were reported. These experiments did suggest that 
in mosquito-transmitted propagation of these mixed infections, either each single 
strain or the mixture could be transmitted; whether this was due to differences in 
circulating gametocyte populations or vector impacts was unresolved. 
 The authors of the original study with mixed P. vivax infections in human 
populations analysed in this work concluded that within wide individual variation, the  
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overall pattern of all observed relapses in mixed-strain infections represented a  
combination of the two strain-specific responses; however, these conclusions were 
based solely on a qualitative assessment of the overall respective clinical courses 
(Cooper et al. 1950). Our analysis of the incubation period concurs with these 
observations, and we also find that the incubation period shows significant differences 
between the mixed and single-strain infections. Consideration of the time-to-first 
relapse, however, suggests that the mixed strain infections are only marginally 
different (RMST analysis) or indistinguishable (IRR analysis) from single-strain 
infections with the Chesson strain. 
 Although poorly understood, hypnozoite re-activation is likely a different 
biological process from incubation (Markus 2012), so the results from the relapse 
analysis may not be directly comparable to other measures of virulence.  Qualitative 
comparison of the survival curves in Figure 13 suggests that the earlier part of the 
mixed-infection curve more closely follows, but is not equivalent to, that of Chesson 
strain infections. However, our analysis is unable to differentiate between two 
potential mechanisms: coordinated relapse between genetically diverse hypnozoites, 
or simply the first result of having two superimposed hypnozoite relapse curves. 
 Consensus about clonal diversity within relapses has been elusive (Imwong et al. 
2007, 2012), and conclusions may be highly dependent on the specific probes used to 
compare parasite-relatedness (Restrepo et al. 2011). Some of these observed 
differences are also potentially due to primaquine treatment (de Araujo et al. 2012), as 
different strains may have differing drug susceptibility (Goller et al. 2007). However, 
it appears clear that some parasite sub-populations that are more prone to relapse, and 
that there can be extensive diversity of parasites within relapses (Lin et al. 2012). 
Critically, relapse epidemiology has been highlighted as a key gap in control of this 
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parasite (Ferreira et al. 2007, Havryliuk and Ferreira 2009), and could present a 
critical barrier for the global elimination of all malaria species (Arnott et al. 2012).  
 The concordance of these epidemiological results with molecular studies provides 
evidence for a policy to prioritize surveillance and primaquine treatment specifically 
directed towards foci of long-relapse genotypes, thereby minimizing their impact on 
global P. vivax population structures towards global malaria elimination. 
 The late WE Collins (US-CDC) indicated that he was not aware of any 
unpublished studies with simultaneous mixed inoculations in primate models at the 
CDC malaria research labs; (Collins 2013b) the data in this current analysis therefore 
likely represent the sum of all that have been collected in both humans and non-
human primates. 
 
Murine models 
 In discussion of the mixed P. yoelii infections, the original study authors note that 
while the mild strain preferentially infected only reticulocytes even in fatal outcomes, 
and the virulent form ‘overwhelmingly’ infected mature erythrocytes, mixed 
infections initially showed parasitemias in both RBC stages, which then progressed in 
the four surviving animals to be predominately composed of infected reticulocytes 
(Hargreaves et al. 1975). 
 A range of modern studies with rodent malaria models has produced ambiguous 
results. Some studies have suggested intense competition between distinct clones so 
that potentially the more virulent clone in mixed-infections can fully dominates the 
clinical course; others have shown attenuation of more-virulent strains in competitive 
scenarios. Extensive modelling studies have suggested that general mixed infections 
may show two differing regimes: one in acute infections, and another suite of 
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interactions in chronic infections as the host’s immune systems begins to generate 
strain-specific response factors (Alizon and van Baalen 2008).  
 Bell and co-authors concluded that mixed infections with P. chabaudi have 
greater virulence than single clone infections, as measured by weight loss and red 
blood cell count (anaemia level) (Taylor et al. 1998). Our analyses of these data does 
not show a significant difference in mortality; however, a pooled analysis of both P. 
chabaudi experiments confirms the original authors’ results using mortality as a direct 
outcome, and suggest a ~40% increased risk of mortality in mixed infections across a 
range of parasite clones.  
 However, our results suggest that within these parasite lineages, RBC and weight 
loss metrics may only capture a portion of the complexity in the measurement of 
‘virulence’; within parasite triads, we find mortality in mixed-strain infections is not 
increased, but equivalent to mortality in infections with the more virulent strain in P. 
chabaudi infections. This suggests that use of survival models allows more 
comprehensive population-level effects to be assessed across the entire time course of 
infections, and avoids the need to choose potentially biased time points for 
comparisons (Hosmer et al. 2011).  
 Our results reconcile these P. chabaudi experiments with mathematical models 
which have suggested that host mortality is strongly driven by the virulence of the 
more virulent strain within an infection (Alizon and van Baalen 2008), but suggests a 
fundamental limit may exist in virulence. Comparison of the risk ratios between the 
CB/AS triad (RR = 2.5) and all mixed/pure infections (RR =1.4) among all studied 
strains, supports the findings of Alizon which suggest that the antigenic distance 
between strains has critical impacts (Alizon and van Baalen 2008). These 
mathematical models suggest that there may be a ‘sweet-spot’ where maximum 
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competition occurs- if strains are highly antigenically divergent, they can parasitize 
essentially independent niches within the host with subsequent limited need for 
competition; whereas highly related parasites are too similar to be differentiated by 
general immune responses. It should be noted that the parasites in the work of Bell et 
al. are described as ‘…genetically (and antigenically) district at multiple loci’ (Bell et 
al. 2006). While the phylogenetics of P. chabaudi has been examined, these 
laboratory isolates were specifically not included (Ramiro et al. 2012), so the 
antigenic distances are unknown. 
 The remarkable consistency of results with the CB/AS strains between the two 
different experiment sets should be noted, especially considering limited source data, 
a 10-year lag between experiments with associated parasite passages, a 100-fold 
difference in inocula, and Bell et al.’s report of a mutation in the msp-1 gene (a key 
mediator of erythrocyte invasion) within the CB strain (Bell et al. 2006). This 
replication, even within inherent limitations of data reporting, greatly strengthens 
these results (Palmer 2000). It is also intriguing that the AS strain was originally 
created by forced selection for pyrimethamine resistance; the causal impact of this 
drug-resistance selection on the observed virulence however is unknown.  
 
Survivorship curves for semi-quantitative categorization of strains 
 In the ecological and demographic literature, plots of survival within populations 
by age, called survivorship curves, allow populations to be categorized into three 
idealized life courses (referred to as type I, II and III curves) (Pianka 2011); see 
Figure 17.  Type III curves are categorized by a large number of mortality events 
early in the time course; type II by a relatively constant rate of events; and type I by 
generally low ‘failure’ rate until the oldest age classes. 
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Figure 17. Idealized ecological/demographic survivorship curves. 
 
 Examination of the survival curves within this study (especially P. yoelii) and 
Figure 13 (with allowances for the crossing curves) closely mimic these classes of 
survivorship curves, although the underlying mechanisms are unrelated. We suggest 
that future studies should consider this general schema for classification of virulence 
for two reasons. First, it allows examination for population-level effects and ‘smooths 
out’ individual-level variation in responses. Secondly, it inherently captures the 
complex interplay between host and parasites to more comprehensively capture the 
composite endpoint of ‘virulence’. Finally, several different metrics have been 
suggested to allow quantitative comparisons between the convexity of survivor 
curves, and have potentially utility in directly classifying the virulence of parasite 
populations (Anson 2002). 
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Contrasts 
 We find that amongst all the limited set of P. vivax (incubation) and P. yoelii 
infections, the survival curves at a population-level are intermediate between the 
clones, and are not dominated by the more virulent infection. However, the survival 
curves in mixed infections are more similar to the more virulent clones as assessed by 
log-rank values, and risk/hazard incidence ratios. This strongly suggests that highly 
virulent clones have their virulence attenuated by the presence of less-virulent clones. 
In line with ample evidence from models and evolutionary theory this is likely due to 
the competition for resources within the host bloodstream. However, these 
comparisons have been made with clones from the extremes of what is likely a wide 
continuum of virulence.  
 Our results from analysis of the much larger set of experiments using P. chabaudi 
suggests greater nuances in interactions between strains, and we find that mortality 
and time-to-event in mixed-strain infections are both indistinguishable from those of 
virulent-strain single infections. This is in sharp contrast to the results from P. yoelii 
experiments, with similar triad-wise sample sizes.  A potential explanation for these 
differences comes from a range of models that have suggested different malaria 
species may exhibit differing specificity age-classes of red blood cells (McQueen and 
McKenzie 2004, 2006, Mideo et al. 2008). The blood stages parasites within the 
current study display differential blood cell preferences: P. vivax and P. yoelii 
generally infect the youngest RBC stages (reticulocytes) (McKenzie et al. 2002), 
whereas P. chabaudi (like P. falciparum) has limited specificity, and readily infects 
both reticulocytes and normocytes (Snounou et al. 1992).  
 These divergent dynamics suggest the possibility that virulence may have 
different underlying mechanisms in P. vivax-like and P. falciparum-like parasites. 
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This hypothesis is consistent with data suggesting that immunity and RBC dynamics, 
which differ greatly between the parasite ‘types,’ are both important contributors to 
competitive ability and parasite dynamics. This suggests that maximal competitive 
advantage may hit a fundamental limit, driven primarily by limited numbers of 
susceptible RBCs in P. vivax-type infections, so virulent strains can only out-compete 
to a certain and limited extent. In contrast, in P. falciparum-type infections, virulence 
in mixed infections is far less constrained and rapidly approaches that of  ‘pure’ 
infections with virulent strains. The consistency of these effects across a range of 
parasite virulence in P. chabaudi isolates suggests these findings are robust. 
 However, other experiments and models of P. chabaudi reach differing 
conclusions and suggest the evolutionary trajectory of higher-virulence strains within 
a mixed strain infection are most impacted by both burst size (number of progeny per 
merozoite) in addition to differential interactions with host immunity (Mideo et al. 
2011). The importance of burst size in human infections is circumstantially supported 
by an early study with the specific P. vivax strains included in this analysis: amongst 
200 infected red blood cells examined from diverse infections for each strain, the St. 
Elizabeth strain had a median of 14 (95% CI: 14 to 14; range 9-20) merozoites; and 
the more virulent Chesson strain had a median of 16 merozoites (95% CI: 16 to 18; 
range 10 to 24); Mann-Whitney test for differences, p < 0.001; authors’ calculations 
from data in (Wilcox et al. 1954). Similar values have been reported for other P. vivax 
strains with similar differences in virulence: a milder Dutch strain produced on 
average 12-13 merozoites, whereas the virulent Madagascar strain produced on 
average 17-18 merozoites per cycle (Swellengrebel and De Buck 1938). 
 These inconsistencies have been explicitly addressed in the elegant models of P. 
vivax blood-stage dynamics of McQueen, which suggest that RBC-stage specificities 
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are of only limited importance, and that host immunity must be a critical component 
in keeping P. vivax from being as virulent/lethal as P. falciparum (McQueen 2010), 
although this paradigm is eroding (Baird 2013). In spite of the analytical limitations 
of these data, our results suggest that virulence proxies in murine malaria may not be 
fully capturing all types of virulence, and a broader selection of endpoints should be 
considered. 
 
Limitations 
 There are several limitations of this analysis. Firstly the P. vivax and P. yoelii 
studies are based on analysis of secondary data with limited experimental detail in the 
original reports. Additionally, all murine experiments used blood-transfer via syringe 
and not transmission via infected vectors, which has the potential to impact parasite 
dynamics (Paul et al. 2004, Nkhoma et al. 2012). Moreover, different species of 
Plasmodium have also evolved independent pathways to counter the same stressor; 
for example, chloroquine resistance in P. falciparum and P. vivax, and parasite 
immune evasion strategies, both likely involve independent pathways in different 
species (Carlton et al. 2002, Lehane et al. 2012).  
 Plasmodium vivax and the murine studies were limited to reporting of events as 
integer days, while mortality events may have occurred at intermediate points; 
however randomization of reported times within 0.2 day did not impact the 
conclusions (data not shown). Additionally, the endpoint of the P. chabaudi studies 
was either mortality or euthanasia if extreme morbidity was observed; it is therefore 
possible that assessment of morbidity could have been variable between the 
experiments. Additionally, other authors have suggested that some P. yoelii-infected 
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animals are able to tolerate very high parasitemia before succumbing several days 
later (Knowles and Walliker 1980).  
 Recent studies have also suggested that parasite passage through anopheline 
vectors can modulate virulence (Spence et al. 2013), and competitive advantage 
within a host also increases a parasite clone’s ability to infect vectors and hence 
population dispersal in rodent models (de Roode et al. 2005). Therefore syringe-
induced infections could represent extremes in virulence that may not reflect natural 
systems (Mideo et al. 2011).  Lastly, many of the comparisons in the murine models 
were made using a small number of animals per treatment group, and not finding an 
effect in some groups is potentially due to sample size limitations. 
 
5.6 Conclusions and public health impacts 
 These results tie together human and murine experimental studies, and also 
suggest that different dynamics could exist between malaria species dependent on 
blood-stage cell specificities. These ‘slippages’ suggest research areas that could 
provide important insights into intra-host malaria dynamics, and could be prioritized 
in planning new murine challenge studies. Our results suggest at least some of these 
conflicting results could be partially addressed by consideration of a more diverse set 
of endpoints beyond comparisons of mean anaemia or parasitemia between groups 
(Nakagawa and Cuthill 2007). While hampered by crossing survival curves and zero-
event categories, which may be unavoidable in some systems, our analysis suggests 
possible fuller use of data could maximize the utility of these very complex and 
experimentally demanding experiments. 
  While the inherent limitations of some of these model systems have been 
recognized (White et al. 2010), they provide invaluable insight into parasite 
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evolutionary dynamics within a host, and the main conclusion from a comprehensive 
review is that there should be closer linkages between human studies and animal 
models, to allow the development of truly synergistic research programs (Langhorne 
et al. 2011). While virulence management has been highlighted as a potential key 
contribution from evolutionary biology especially in malaria, it has been suggested 
this paradigm has had limited impact on clinical practice (Restif 2009). Our results 
highlight the critical interplay between these fields, and reinforce recent calls for 
greater evolutionary thinking in malaria control, drug policy, and ‘containment’ of 
resistance (Read et al. 2011). Additionally, it has been proposed that reductions in 
population-level prevalence of multiple-strain infections could decrease inherent 
pressures on the evolution of virulence and drug resistance, and this suggests that 
greater emphasis should be placed on surveillance of intra-infection diversity 
(Havryliuk and Ferreira 2009). 
  Finally, these results hint that evolutionary drivers of strain competition and 
virulence could differ between P. vivax and P. falciparum. This suggests several 
broad avenues for future studies in animal models. A head-to-head comparison in the 
same laboratory between reticulocyte-specific and red blood cell generalist parasites 
encompassing similar differences in virulence could provide greater evidence. These 
results could be critical importance for the planning of species-specific policies for 
drug-resistance mitigation, and towards global malaria elimination for all malaria 
species. 
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Chapter 6: Note on the origin of the Madagascar strain of 
Plasmodium vivax 
 
A version of this work has been published as: Lover AA (2014), Note on the 
origin of the Madagascar strain of Plasmodium vivax. American Journal of 
Tropical Medicine and Hygiene 91(6), 1283. 
 
6.1 Introduction  
 Early malariotherapy studies suggested that many persons of African descent had 
inherent resistance to infections with Plasmodium vivax; the biological basis of this 
apparent immunity was later correlated with the ‘Duffy antigen’ (Zimmerman et al. 
2013).  For several decades, it was assumed that the widespread lack of this 
erythrocyte surface protein was an important barrier to P. vivax infections throughout 
sub-Saharan Africa. However, recent studies have established the potential for strains 
of Plasmodium vivax in Madagascar to infect Duffy-negative populations (Ménard et 
al. 2010), and sensitive PCR-based screening suggests a previously unrecognized 
burden of this parasite in multiple locations in sub-Saharan Africa (Fru-Cho et al. 
2014, Ngassa Mbenda and Das 2014).  
 
6.2 Letter 
 The identification of these P. vivax infections in Africa has highlighted a further 
major gap in vivax epidemiology: there is a dearth of data concerning any P. vivax 
parasites from Africa. However, one of the most widely studied strains used during 
the malariotherapy-era was the Madagascar strain, used at the site at Horton Hospital, 
UK from 1923- ca. 1970. This isolate has seen extensive study and re-analysis (James 
et al. 1936, Glynn and Bradley 1995), but there has been considerable debate about 
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the origin of this strain, and two recent papers specifically suggest the origin may well 
be elsewhere (Baird 2013, Battle et al. 2014).  
 However, further detail is provided in the work of Percy G. Shute, the 
malariologist who personally interviewed and treated the index patient for this strain. 
In his comprehensive report (which is not readily available) related to this clinical 
isolate, he states: 
…the technique [of malariotherapy] was employed in England, with a 
variety of strains obtained by one of us (PGS) from sailors and others 
suffering from malaria and entering the Port of London. Eventually a ship 
arrived from Madagascar with several fever patients one board; of them - a 
Lascar (Indian) seaman - had a high fever and exhibited many P. vivax 
parasites in his blood. His blood was inoculated into a patient in a mental 
hospital in London; fever and parasites appeared 10 days later and 
gametocytes were detected some days afterwards. Mosquitoes (Anopheles 
atroparvus) were fed on him and they became infected. The infection was 
then passed to other patients and thus the « Madagascar strain » was 
established (…). 
 
The precise locality in Madagascar where the Indian seaman contracted 
the infection is impossible to determine. Ten days after his ship had left 
Madagascar, on the passage to England, he developed fever, but malaria 
was not diagnosed until he arrived at Tilbury (Port of London). He was 
then found to be suffering from a quotidian fever with temperatures rising 
to 40°- 41° C. He gave no previous history of malaria and this attack was 
unlikely to have been a relapse for the reason that his paroxysms occured 
[sic] daily, as in a primary attack; whereas the fever in relapses is tertian 
from the start. For these reasons, it is most probable that the designation « 
Madagascar strain » is geographically correct. (Shute et al. 1978). 
 
 These differences in fever periodicity between primary infections and relapses are 
strongly supported by other researchers and clinician in a range of settings e.g. (Noe 
et al. 1946, Covell and Nicol 1951, Adak et al. 2001). Moreover, meticulous study by 
James using the Madagascar strain itself reinforced Shute’s observations (James et al. 
1936). This clinical behaviour is likely due likely due to the slow establishment of 
well-synchronized parasite subpopulations in primary infections (Warrell and Gilles 
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2002), and the emergence of clonal hypnozoites in relapses (Chen et al. 2007) 
respectively.  
 
6.3 Conclusions 
 These observations strongly suggest that the wealth of irreplaceable clinical and 
epidemiological data collected during malariotherapy treatments using the 
Madagascar strain have important and critical utility, and should be combined with 
modern phylogenetic and molecular studies (Li et al. 2001, Neafsey et al. 2012)  to 
inform a research agenda into the epidemiology of African P. vivax. Finally, while the 
original geographic origin of P. vivax remains of considerable debate, recent studies 
suggest an African origin (Liu et al. 2014); and there have been multiple suggestions 
that there may be an unrecognized reservoir in Africa e.g. (Rosenberg 2007). A fuller 
and comprehensive understanding of these parasite populations, along their human 
and non-human primate reservoirs, will be a crucial next-step for global malaria 
elimination programs. 
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Chapter 7: Conclusions 
 
In 1985, the doyen of the ‘golden era’ of malariology noted: 
The old generation of 'blood, mud and sweat' malariologists has nearly 
disappeared and much of their experience has been largely forgotten. The author 
of the present book hopes that he has contributed to forging a link between the not 
too distant past and the new generation of specialists in tropical community 
health.  (Bruce-Chwatt 1985) 
 
7.1 Introduction 
 My initial reaction to reading about malariotherapy was one of amazement and 
incredulity- using one potentially fatal infectious disease to treat another? Did it really 
work? How did anyone know? The more I delved into the subject, the larger the 
breadth of the historical literature became, with hundreds of papers referencing 
hundreds of still-earlier works. It became readily apparent that many of these reports 
had had limited reconsideration in subsequent decades, with the conclusions simply 
cited as ‘truth’. This led to another series of questions- how robust were these results 
and subsequent conclusions? Was it even possible to know at this remove, and was 
there analysable data that might add anything within a modern framework? Indeed, 
huge volumes of original working papers, colonial health board reports, plus WHO 
and League of Nations report series were readily available online and in the NUS 
archives. 
 While there has been some systems-level thinking in malaria control since Ronald 
Ross’s earliest models, the contentious debates of the early 20th century regarding 
whether the proper focus should be on the parasite or upon the vector, highlight the 
serious divisions that have occurred within malaria control (Stapleton 2009). The 
burgeoning intersections between epidemiology, entomology, ecology, and  
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parasitology have in recent years highlighted these false dichotomies, towards an 
understanding that the entire dynamic and continually shifting ‘web of transmission’ 
itself has to be unstitched. To this end, coordinated and synergistic combinations of 
all appropriate tools, deployed effectively, will be crucial for elimination. This thesis 
aimed to forge a small link in this chain of knowledge, and to highlight a few areas 
worthy of further exploration.  
 
7.2 Summary of findings and implications for future work  
 Chapter 2 of this thesis has explored the measurable epidemiological impacts of 
geographic origin of Plasmodium vivax strains, and largely confirms results from 
earlier qualitative assessments of these effects, but finds subtleties in geographic 
epidemiology that been lost due to data aggregations. However, this analysis was 
limited by the historical and descriptive nature of these parasite strains; further work 
could try to connect these results to modern molecular and genetic studies, if samples 
from any of these parasites populations can be located and extracted, as recently 
suggested (Collins 2013a). Within the limitations of subsequent parasite evolution, 
this could allow a direct linkage between observed epidemiological measures and 
parasite data, to prioritize surveillance activities towards malaria elimination. 
 Chapter 3 of this work examines the evidence for sporozoite-dependent effects on 
incubation periods in P. vivax infections by re-analysis of historical challenge studies. 
In direct contrast to accumulated knowledge, we find extremely limited evidence for 
effects at any plausible naturally occurring exposures. In concurrence with other 
recent studies, these results suggest that parasite strain itself and parasite-vector 
interactions have larger quantitative effects than sporozoite dose. These findings 
highlight the complexity of the Plasmodium-Anopheles interface, and suggest that 
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greater consideration of these interactions could be critical to ensure that human 
challenge studies for vaccine and malaria prophylaxis development programs have 
maximal congruence with natural transmission. 
 In Chapter 4, well-defined and readily implementable distributions that capture 
event times in experimental P. vivax infections are presented. These results suggest 
that the default parameterizations in many mathematical models of P. vivax 
transmission may incompletely capture the diversity within natural parasite 
populations, and that ‘better’ distributional choices can have large impacts on model 
outputs. Finally these results provide some evidence that long-latent infections have a 
closer tie to general incubation periods than they do to relapse. Future modelling 
studies should consider use of these optimal distributions, and the impact of these 
distributional choices should be explored within comprehensive mathematical and 
statistical models. 
 Chapter 5 of this thesis explores the impacts of mixed-strain infections in both 
human and murine experimental challenges. The results from P. vivax concur with 
some animal models and ecological theory, but also suggest that there are potentially 
large differences in virulence evolution between parasites that target normocytes and 
those that target reticulocytes. These differences could be explored in greater detail 
via head-to-head comparison of diverse murine malaria species, which could 
potentially provide an evidence base for parasite-specific virulence control measures. 
 Finally, Chapter 6 clarifies the most probable origin of the canonical Madagascar 
strain of P. vivax. This question has taken on renewed importance with the recent 
realization that this parasite may have far greater prevalence in Sub-Saharan Africa 
than previously believed, including a non-human primate reservoir (Liu et al. 2014). 
Linking the extensive historical data acquired using the Madagascar strain to modern 
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African P. vivax could have important implications for the future ‘end-game’ of 
malaria elimination in Africa. 
 Future research programs must confront the enigmatic biology of sporozoites in 
vectors and humans; and of gametocytes and hypnozoites in humans. Specifically, 
while extensive work is currently on-going to explore the fate of injected sporozoites 
in murine model systems, the inability to propagate P. vivax in laboratory settings will 
limit the study of vivax-specific sporozoite biology. The results in this thesis suggest 
important vector species-specific impacts on sporozoites that should be more fully 
explored, especially using non-human primate models (Joyner et al. 2015).  
 The timing and number of gametocytes produced in malaria infections are 
critically important factors in determining transmission success; while this life stage 
has had extensive study in P. falciparum infections, knowledge within P. vivax 
infections is far more limited. Moreover, production of gametocytes before or rapidly 
after the onset of clinical symptoms provides ample opportunity for continued 
transmission. While malariotherapy studies did not generally report gametocytemia 
data, studies with the Madagascar strain did find increases in gametocyte production 
in this strain after long-term mosquito-to-human propagation (Glynn and Bradley 
1995); the evolutionary drivers and impact on transmission of these changes, and any 
geographic variation in gametocyte production amongst P. vivax strains remain 
important topics worthy of further study. 
 Finally, hypnozoite biology must progress beyond the current ‘black-box.’ The 
triggers for hypnozoite activation need to be identified; and population-level 
timespans necessary for surveillance in specific elimination settings, and for follow-
up within clinical efficacy studies need to be carefully delineated, potentially as 
recently implemented in Mexico (Gonzalez-Ceron et al. 2013). Finally, recent 
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modelling studies have found that either 3 or 6 classes of hypnozoites most closely 
explained observed epidemiology in India; however, the potential biological 
underpinnings of these results remain obscure, and suggest important areas for linking 
regional epidemiology with parasite biology (Roy et al. 2013). 
 
7.3 Final statement 
 The chapters of this thesis provide a useful set of epidemiological studies to 
expand what is currently known about Plasmodium vivax with the potential to assist 
in developing an evidence-based research agenda for control of this parasite, and 
towards global elimination of all malaria species. 
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